Source: http://madcowspontaneousnot.blogspot.com/2006/06/mad-cow-feed-recall-usa-albertville-al.html
Timestamp: 2017-04-26 13:38:00
Document Index: 225487869

Matched Legal Cases: ['art 9', '§1', 'art1', 'art 589', 'art 589', 'art 589']

MADCOW DISEASE USA SPONTANEOUS OR FEED ?: MAD COW FEED RECALL USA Albertville, AL -- June 16, 2006 -- H.J. Baker & Bro.
Tuesday, June 20, 2006MAD COW FEED RECALL USA Albertville, AL -- June 16, 2006 -- H.J. Baker & Bro.Subject: MAD COW FEED RECALL USA Albertville, AL -- June 16, 2006 -- H.J. Baker & Bro. Date: June 20, 2006 at 6:55 am PST MAD COW FEED RECALL USA Albertville, AL -- June 16, 2006 -- H.J. Baker & Bro.Recall -- Firm Press ReleaseFDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company. This listserv covers mainly Class I (life-threatening) recalls. A complete listing of recalls can be found in the FDA Enforcement Report at: http://www.fda.gov/opacom/Enforce.htmlHJ Baker and Bro., Inc. Announces National Recall of Three Animal Feed Products Containing Prohibited Ingredients Contact: Mark Hohnbaum 501-664-4870FOR IMMEDIATE RELEASE -- Albertville, AL -- June 16, 2006 -- H.J. Baker & Bro. has announced today that in cooperation with the US Food & Drug Administration (FDA) it has begun efforts to retrieve PRO-PAK WITH PORCINE MEAT AND BONE, PRO-LAK, AND PRO-AMINO II produced at its Albertville, AL facility. These products are used as an ingredient in the manufacturing of livestock feed, including feed for dairy animals. This action is being taken to address potential risk of unintentional contamination with ruminant derived protein that may have occurred at this facility from August 2005 to June 2006. Certain mammalian protein is prohibited for use in ruminant feed. These products were distributed in bulk or bags to feed manufacturers and dairy farms in Georgia, Kentucky, Michigan, Florida, Alabama, Tennessee, Mississippi, California, and Louisiana.If you have received any of these products, discontinue their use immediately. Quarantine the product so that it cannot be inadvertently used in the manufacture of feeds and contact the manufacturer at 501-664-4870 for further instructions."All production and shipment of these products from the Albertville mill have ceased and all of our customers are being notified of the potential contamination. With the advice and support of the FDA, we were able to respond rapidly to address this matter," said Christopher Smith, President & CEO.H.J. Baker & Bro., Inc., headquartered in Westport, CT, has served the fertilizer and animal feed industries since the Company was founded in 1850.####FDA's Recalls, Market Withdrawals and Safety Alerts Page: http://www.fda.gov/opacom/7alerts.htmllets see here now, we have mad cows in Alabama, we have mad cow feed in Alabama, however JUST another spontaneous event of more BSe. ...TSS#################### https://lists.aegee.org/bse-l.html ####################June 20, 2006, 5:13PM Feed Recalled Over Mad Cow Violation© 2006 The Associated PressWASHINGTON — Livestock feed ingredients shipped to nine states may have been contaminated with cattle remains in violation of a 1997 ban to protect against mad cow disease, a manufacturer said Tuesday.H.J. Baker & Bro. Inc. said it was recalling three livestock feed ingredients, including two used to supplement feed given to dairy cows. A sample tested by the Food and Drug Administration was positive for cattle meat and bone meal, said Mark Hohnbaum, president of the Westport, Conn.-based company's feed products group."This is very concerning to us. This isn't something that happens to us. We are very serious about food safety," Hohnbaum said.Mad cow disease is only known to spread when cows eat feed containing brain and other nerve tissue from infected cattle. Protein from cattle was commonly added to cattle feed to speed growth until the ban largely outlawed the practice.Cattle tissue may have contaminated two feed ingredients given to dairy cows _ Pro-Lak and Pro-Amino II _ made by H.J. Baker between August 2005 and June. The third of the recalled ingredients, Pro-Pak with Porcine Meat and Bone, was mislabeled. It is used in poultry feed.The company announced the recall in the wake of ongoing FDA inspections of its Albertville, Ala. plant, Hohnbaum said. The inspections have found manufacturing and clerical issues, he added.The company shipped the ingredients to feed manufacturers and dairy farms in the following states: Alabama, California, Florida, Georgia, Kentucky, Louisiana, Michigan, Mississippi and Tennessee. The company is notifying its customers of the voluntary recall. It does not know how much of the feed ingredients it sold, Hohnbaum said.___On the Net:Food and Drug Administration animal feed information:http://www.fda.gov/cvm/animalfeed.htmhttp://www.chron.com/disp/story.mpl/ap/fn/3987413.htmlSubject: USDA, SPONTANEOUS MAD COW DISEASE, THE TOOTH FAIRY AND SANTA CLAUSDate: June 12, 2006 at 5:18 am PSTIF we all believe the BSe that the USDA is trying to put out now about atypical BSE in USA cattle just arising spontaneously, then we all should believe in the tooth fairy and santa claus as well.IF USA scrapie transmitted to USA cattle long ago in experiments in a lab in Mission Texas did not produce UK BSE, but something very different, then why would USA TSE cattle produce the UK human version of mad cow i.e. nvCJD? IT wouldn't. USA sporadic cjd is increasing, the USA also has atypical human cases of unknown origin as well?THERE are over 20 strains of scrapie, plus the atypical in sheep, and these strains are increasing in numbers.SCRAPIE, CWD, AND TSE IN CATTLE i.e. ANIMAL TSE RAMPANT IN USA FOR DECADES, and amplified via rendering and feeding practices, where USDA triple firewalls against BSE were nothing more than a mere smoke screen.NO test tube TSE by either Prusiner or Soto, to date, have ever produced a TSE identical to the sporadic CJD. IN fact, no test tube TSE has ever been produced that resembles _any_ natural field TSE.IF you feed BSE tainted materials to cattle and primate, you have BSE and nvCJD. IF you feed USA sheep strain to USA cattle, you get USA TSE. IF you feed USA tainted cattle to humans, you get USA mad cow disease. IF you feed sporadic CJD to primate you get a CJD infected primate. NOTHING spontaneous about it at all.USA is in a very unique situation. there are more documented TSE in different species than any other country, all of which have been rendered and fed back to animals for human and animal consumption, for decades. Millions exposed, and of these Millions, how many surgical and dental procedures have been done on these exposed, to pass on to others, via the 'friendly fire' mode of transmission?IF, the spontaneous TSE was true, then this would be Prusiner and everyone else that is trying to cash in on this agent with there TSE rapid test, this would be there dream come true. IT would require mandatory BSE/TSE testing of all species, due to the fact you could not ever eradicate it through any intervention. BUT, then again, the spontaneous TSE is like believing in the tooth fairy or santa claus will be arriving at your house this year.How long can this sharade continue $How many more will become exposed and have to die $Medical Sciences Identification of a second bovine amyloidotic spongiform encephalopathy: Molecular similarities with sporadic Creutzfeldt-Jakob diseaseCristina Casalone *, Gianluigi Zanusso , Pierluigi Acutis *, Sergio Ferrari , Lorenzo Capucci , Fabrizio Tagliavini ¶, Salvatore Monaco , and Maria Caramelli * *Centro di Referenza Nazionale per le Encefalopatie Animali, Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna, 148, 10195 Turin, Italy; Department of Neurological and Visual Science, Section of Clinical Neurology, Policlinico G.B. Rossi, Piazzale L.A. Scuro, 10, 37134 Verona, Italy; Istituto Zooprofilattico Sperimentale della Lombardia ed Emilia Romagna, Via Bianchi, 9, 25124 Brescia, Italy; and ¶Istituto Nazionale Neurologico "Carlo Besta," Via Celoria 11, 20133 Milan, ItalyEdited by Stanley B. Prusiner, University of California, San Francisco, CA, and approved December 23, 2003 (received for review September 9, 2003)Transmissible spongiform encephalopathies (TSEs), or prion diseases, are mammalian neurodegenerative disorders characterized by a posttranslational conversion and brain accumulation of an insoluble, protease-resistant isoform (PrPSc) of the host-encoded cellular prion protein (PrPC). Human and animal TSE agents exist as different phenotypes that can be biochemically differentiated on the basis of the molecular mass of the protease-resistant PrPSc fragments and the degree of glycosylation. Epidemiological, molecular, and transmission studies strongly suggest that the single strain of agent responsible for bovine spongiform encephalopathy (BSE) has infected humans, causing variant Creutzfeldt-Jakob disease. The unprecedented biological properties of the BSE agent, which circumvents the so-called "species barrier" between cattle and humans and adapts to different mammalian species, has raised considerable concern for human health. To date, it is unknown whether more than one strain might be responsible for cattle TSE or whether the BSE agent undergoes phenotypic variation after natural transmission. Here we provide evidence of a second cattle TSE. The disorder was pathologically characterized by the presence of PrP-immunopositive amyloid plaques, as opposed to the lack of amyloid deposition in typical BSE cases, and by a different pattern of regional distribution and topology of brain PrPSc accumulation. In addition, Western blot analysis showed a PrPSc type with predominance of the low molecular mass glycoform and a protease-resistant fragment of lower molecular mass than BSE-PrPSc. Strikingly, the molecular signature of this previously undescribed bovine PrPSc was similar to that encountered in a distinct subtype of sporadic Creutzfeldt-Jakob disease.--------------------------------------------------------------------------------C.C. and G.Z. contributed equally to this work.To whom correspondence should be addressed.E-mail: salvatore.monaco@mail.univr.it. www.pnas.org/cgi/doi/10.1073/pnas.0305777101http://www.pnas.org/cgi/content/abstract/0305777101v1: J Infect Dis 1980 Aug;142(2):205-8Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman primates.Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC.Kuru and Creutzfeldt-Jakob disease of humans and scrapie disease of sheep and goats were transmitted to squirrel monkeys (Saimiri sciureus) that were exposed to the infectious agents only by their nonforced consumption of known infectious tissues. The asymptomatic incubation period in the one monkey exposed to the virus of kuru was 36 months; that in the two monkeys exposed to the virus of Creutzfeldt-Jakob disease was 23 and 27 months, respectively; and that in the two monkeys exposed to the virus of scrapie was 25 and 32 months, respectively. Careful physical examination of the buccal cavities of all of the monkeys failed to reveal signs or oral lesions. One additional monkey similarly exposed to kuru has remained asymptomatic during the 39 months that it has been under observation.PMID: 6997404http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6997404&dopt=AbstractAtypical cases of TSE in cases of TSE in cattle and sheep cattle and sheep H. De H. De Bosschere Bosschere CODA/CERVA CODA/CERVA Nat. Ref. Lab. Vet. Nat. Ref. Lab. Vet. TSEs TSEs Belgiumhttp://www.var.fgov.be/pdf/1100_TSEDAY.pdfUSDA 2004 ENHANCED BSE SURVEILLANCE PROGRAM AND HOW NOT TO FIND BSE CASES (OFFICIAL DRAFT OIG REPORT)snip...CATTLE With CNS Symptoms Were NOT Always Testedsnip...Between FYs 2002 and 2004, FSIS condemned 680 cattle of all ages due to CNS symptoms. About 357 of these could be classified as adult. We could validate that ONLY 162 were tested for BSE (per APHIS records. ...snip...WE interviewed officials at five laboratories that test for rabies. Those officials CONFIRMED THEY ARE NOT REQUIRED TO SUBMIT RABIES-NEGATIVE SAMPLES TO APHIS FOR BSE TESTING. A South Dakota laboratory official said they were not aware they could submit rabies-negative samples to APHIS for BSE testing. A laboratory official in another State said all rabies-negative cases were not submitted to APHIS because BSE was ''NOT ON THEIR RADAR SCREEN." Officials from New York, Wisconsin, TEXAS, and Iowa advised they would NOT submit samples from animals they consider too young. Four of the five States contacted defined this age as 24 months; Wisconsin defined it as 30 months. TEXAS officials also advised that they do not always have sufficient tissue remaining to submit a BSE sample. ...snip...FULL TEXT 54 PAGES OF HOW NOT TO FIND BSE IN USA ;http://www.house.gov/reform/min/pdfs_108_2/pdfs_inves/pdf_food_usda_mad_cow_july_13_ig_rep.pdfHUMAN TSE USA 2005Animal Prion Diseases Relevant to Humans (unknown types?) Thu Oct 27, 2005 12:05 71.248.128.109About Human Prion Diseases / Animal Prion Diseases Relevant to HumansBovine Spongiform Encephalopathy (BSE) is a prion disease of cattle. Since 1986, when BSE was recognized, over 180,000 cattle in the UK have developed the disease, and approximately one to three million are likely to have been infected with the BSE agent, most of which were slaughtered for human consumption before developing signs of the disease. The origin of the first case of BSE is unknown, but the epidemic was caused by the recycling of processed waste parts of cattle, some of which were infected with the BSE agent and given to other cattle in feed. Control measures have resulted in the consistent decline of the epidemic in the UK since 1992. Infected cattle and feed exported from the UK have resulted in smaller epidemics in other European countries, where control measures were applied later.Compelling evidence indicates that BSE can be transmitted to humans through the consumption of prion contaminated meat. BSE-infected individuals eventually develop vCJD with an incubation time believed to be on average 10 years. As of November 2004, three cases of BSE have been reported in North America. One had been imported to Canada from the UK, one was grown in Canada, and one discovered in the USA but of Canadian origin. There has been only one case of vCJD reported in the USA, but the patient most likely acquired the disease in the United Kingdom. If current control measures intended to protect public and animal health are well enforced, the cattle epidemic should be largely under control and any remaining risk to humans through beef consumption should be very small. (For more details see Smith et al. British Medical Bulletin, 66: 185. 2003.)Chronic Wasting Disease (CWD) is a prion disease of elk and deer, both free range and in captivity. CWD is endemic in areas of Colorado, Wyoming, and Nebraska, but new foci of this disease have been detected in Nebraska, South Dakota, New Mexico, Wisconsin, Mississippi Kansas, Oklahoma, Minnesota, Montana, and Canada. Since there are an estimated 22 million elk and deer in the USA and a large number of hunters who consume elk and deer meat, there is the possibility that CWD can be transmitted from elk and deer to humans. As of November 2004, the NPDPSC has examined 26 hunters with a suspected prion disease. However, all of them appeared to have either typical sporadic or familial forms of the disease. The NPDPSC coordinates with the Centers for Disease Control and state health departments to monitor cases from CWD-endemic areas. Furthermore, it is doing experimental research on CWD transmissibility using animal models. (For details see Sigurdson et al. British Medical Bulletin. 66: 199. 2003 and Belay et al. Emerging Infectious Diseases. 10(6): 977. 2004.)http://www.cjdsurveillance.com/abouthpd-animal.htmlSEE STEADY INCREASE IN SPORADIC CJD IN THE USA FROM 1997 TO 2004. SPORADIC CJD CASES TRIPLED, and that is with a human TSE surveillance system that is terrible flawed. in 1997 cases of the _reported_ cases of cjd were at 54, to 163 _reported_ cases in 2004. see stats here;p.s. please note the 47 PENDING CASES to Sept. 2005p.s. please note the 2005 Prion D. total 120(8) 8=includes 51 type pending, 1 TYPE UNKNOWN ???p.s. please note sporadic CJD 2002(1) 1=3 TYPE UNKNOWN???p.s. please note 2004 prion disease (6) 6=7 TYPE UNKNOWN???http://www.cjdsurveillance.com/resources-casereport.htmlCWD TO HUMANS = sCJD ???AS implied in the Inset 25 we must not _ASSUME_ that transmission of BSE to other species will invariably present pathology typical of a scrapie-like disease.snip...http://www.bseinquiry.gov.uk/files/yb/1991/01/04004001.pdfsnip...end full text ;http://www.bseinquiry.gov.uk/files/mb/m11b/tab01.pdfVERY VERY IMPORTANT THING TO REMEMBERDifferences in tissue distribution could require new regulations regarding specific risk material (SRM) removal.Research Project: Study of Atypical BseLocation: Virus and Prion Diseases of LivestockProject Number: 3625-32000-073-07 Project Type: Specific C/AStart Date: Sep 15, 2004 End Date: Sep 14, 2007Objective: The objective of this cooperative research project with Dr. Maria Caramelli from the Italian BSE Reference Laboratory in Turin, Italy, is to conduct comparative studies with the U.S. bovine spongiform encephalopathy (BSE) isolate and the atypical BSE isolates identified in Italy. The studies will cover the following areas: 1. Evaluation of present diagnostics tools used in the U.S. for the detection of atypical BSE cases. 2. Molecular comparison of the U.S. BSE isolate and other typical BSE isolates with atypical BSE cases. 3. Studies on transmissibility and tissue distribution of atypical BSE isolates in cattle and other species.Approach: This project will be done as a Specific Cooperative Agreement with the Italian BSE Reference Laboratory, Istituto Zooprofilattico Sperimentale del Piemonte, in Turin, Italy. It is essential for the U.S. BSE surveillance program to analyze the effectiveness of the U.S diagnostic tools for detection of atypical cases of BSE. Molecular comparisons of the U.S. BSE isolate with atypical BSE isolates will provide further characterization of the U.S. BSE isolate. Transmission studies are already underway using brain homogenates from atypical BSE cases into mice, cattle and sheep. It will be critical to see whether the atypical BSE isolates behave similarly to typical BSE isolates in terms of transmissibility and disease pathogenesis. If transmission occurs, tissue distribution comparisons will be made between cattle infected with the atypical BSE isolate and the U.S. BSE isolate. Differences in tissue distribution could require new regulations regarding specific risk material (SRM) removal.http://www.ars.usda.gov/research/projects/projects.htm?ACCN_NO=4084903.57 The experiment which might have determined whether BSE and scrapie were caused by the same agent (ie, the feeding of natural scrapie to cattle) was never undertaken in the UK. It was, however, performed in the USA in 1979, when it was shown that cattle inoculated with the scrapie agent endemic in the flock of Suffolk sheep at the United States Department of Agriculture in Mission, Texas, developed a TSE quite unlike BSE. 32 The findings of the initial transmission, though not of the clinical or neurohistological examination, were communicated in October 1988 to Dr Watson, Director of the CVL, following a visit by Dr Wrathall, one of the project leaders in the Pathology Department of the CVL, to the United States Department of Agriculture. 33 The results were not published at this point, since the attempted transmission to mice from the experimental cow brain had been inconclusive. The results of the clinical and histological differences between scrapie-affected sheep and cattle were published in 1995. Similar studies in which cattle were inoculated intracerebrally with scrapie inocula derived from a number of scrapie-affected sheep of different breeds and from different States, were carried out at the US National Animal Disease Centre. 34 The results, published in 1994, showed that this source of scrapie agent, though pathogenic for cattle, did not produce the same clinical signs of brain lesions characteristic of BSE.http://www.bseinquiry.gov.uk/report/volume2/chaptea3.htm#820543The findings of the initial transmission, though not of the clinical or neurohistological examination, were communicated in October 1988 to Dr Watson, Director of the CVL, following a visit by Dr Wrathall, one of the project leaders in the Pathology Department of the CVL, to the United States Department of Agriculture. 33http://www.bseinquiry.gov.uk/files/yb/1988/10/00001001.pdfhttp://www.bseinquiry.gov.uk/report/volume2/chaptea3.htm#820546The results were not published at this point, since the attempted transmission to mice from the experimental cow brain had been inconclusive. The results of the clinical and histological differences between scrapie-affected sheep and cattle were published in 1995. Similar studies in which cattle were inoculated intracerebrally with scrapie inocula derived from a number of scrapie-affected sheep of different breeds and from different States, were carried out at the US National Animal Disease Centre. 34 The results, published in 1994, showed that this source of scrapie agent, though pathogenic for cattle, did not produce the same clinical signs of brain lesions characteristic of BSE.3.58 There are several possible reasons why the experiment was not performed in the UK. It had been recommended by Sir Richard Southwood (Chairman of the Working Party on Bovine Spongiform Encephalopathy) in his letter to the Permanent Secretary of MAFF, Mr (now Sir) Derek Andrews, on 21 June 1988, 35 though it was not specifically recommended in the Working Party Report or indeed in the Tyrrell Committee Report (details of the Southwood Working Party and the Tyrell Committee can be found in vol. 4: The Southwood Working Party, 1988-89 and vol. 11: Scientists after Southwood respectively). The direct inoculation of scrapie into calves was given low priority, because of its high cost and because it was known that it had already taken place in the USA. 36 It was also felt that the results of such an experiment would be hard to interpret. While a negative result would be informative, a positive result would need to demonstrate that when scrapie was transmitted to cattle, the disease which developed in cattle was the same as BSE. 37 Given the large number of strains of scrapie and the possibility that BSE was one of them, it would be necessary to transmit every scrapie strain to cattle separately, to test the hypothesis properly. Such an experiment would be expensive. Secondly, as measures to control the epidemic took hold, the need for the experiment from the policy viewpoint was not considered so urgent. It was felt that the results would be mainly of academic interest. 38http://www.bseinquiry.gov.uk/report/volume2/chaptea3.htm#820550http://www.bseinquiry.gov.uk/report/volume2/chaptea3.htmREPORT OF THE COMMITTEE ON SCRAPIEChair: Dr. Jim Logan, Cheyenne, WYVice Chair: Dr. Joe D. Ross, Sonora, TXDr. Deborah L. Brennan, MS; Dr. Beth Carlson, ND; Dr. John R. Clifford, DC; Dr. Thomas F. Conner, OH; Dr. Walter E. Cook, WY; Dr. Wayne E. Cunningham, CO; Dr. Jerry W. Diemer, TX; Dr. Anita J. Edmondson, CA; Dr. Dee Ellis, TX; Dr. Lisa A. Ferguson, MD; Dr. Keith R. Forbes, NY; Dr. R. David Glauer, OH; Dr. James R. Grady, CO; Dr. William L. Hartmann, MN; Dr. Carolyn Inch, CAN; Dr. Susan J. Keller, ND; Dr. Allen M. Knowles, TN; Dr. Thomas F. Linfield, MT; Dr. Michael R. Marshall, UT; Dr. Cheryl A. Miller, In; Dr. Brian V. Noland, CO; Dr. Charles Palmer, CA; Dr. Kristine R. Petrini, MN; Mr. Stan Potratz, IA; Mr. Paul E. Rodgers, CO; Dr. Joan D. Rowe, CA; Dr. Pamela L. Smith, IA; Dr. Diane L. Sutton, MD; Dr. Lynn Anne Tesar, SD; Dr. Delwin D. Wilmot, NE; Dr. Nora E. Wineland, CO; Dr. Cindy B. Wolf, MN.The Committee met on November 9, 2005, from 8:00am until 11:55am, Hershey Lodge and Convention Center, Hershey, Pennsylvania. The meeting was called to order by Dr. Jim Logan, chair, with vice chairman Dr. Joe D. Ross attending. There were 74 people in attendance.The Scrapie Program Update was provided by Dr. Diane Sutton, National Scrapie Program Coordinator, United States Department of Agriculture (USDA), Animal and Plant Health Inspection Services (APHIS), Veterinary Services (VS). The complete text of the Status Report is included in these Proceedings.Dr. Patricia Meinhardt, USDA-APHIS-VS-National Veterinary Services Laboratory (NVSL) gave the Update on Genotyping Labs and Discrepancies in Results. NVSL conducts investigations into discrepancies on genotype testing results associated with the Scrapie Eradication Program. It is the policy of the Program to conduct a second genotype test at a second laboratory on certain individual animals. Occasionally, there are discrepancies in those results. The NVSL conducts follow-up on these situations through additional testing on additional samples from the field and archive samples from the testing laboratories.For the period of time from January 1, 2005, until October 15, 2005, there were 23 instances of discrepancies in results from 35 flocks. Of those 23 instances, 14 were caused by laboratory error (paperwork or sample mix-up), 3 results from field error, 5 were not completely resolved, and 1 originated from the use of a non-approved laboratory for the first test. As a result of inconsistencies, one laboratory’s certification was revoked by APHIS-VS.snip...Infected and Source FlocksAs of September 30, 2005, there were 105 scrapie infected and source flocks. There were a total of 165** new infected and source flocks reported for FY 2005. The total infected and source flocks that have been released in FY 2005 was 128. The ratio of infected and source flocks cleaned up or placed on clean up plans vs. new infected and source flocks discovered in FY 2005 was 1.03 : 1*. In addition 622 scrapie cases were confirmed and reported by the National Veterinary Services Laboratories (NVSL) in FY 2005, of which 130 were RSSS cases. Fifteen cases of scrapie in goats have been reported since 1990. The last goat case was reported in May 2005. Approximately 5,626 animals were indemnified comprised of 49% non-registered sheep, 45% registered sheep, 1.4% non-registered goats and 4.6% registered goats.Regulatory Scrapie Slaughter Surveillance (RSSS)RSSS was designed to utilize the findings of the Center for Epidemiology and Animal Health (CEAH) Scrapie: Ovine Slaughter Surveillance (SOSS) study. The results of SOSS can be found at http://www.aphis.usda.gov/vs/ceah/cahm/Sheep/sheep.htm . RSSS started April 1,2003. It is a targeted slaughter surveillance program which is designed to identify infected flocks for clean-up. During FY 2005 collections increased by 32% overall and by 90% for black and mottled faced sheep improving overall program effectiveness and efficiency as demonstrated by the 26% decrease in percent positive black faced sheep compared to FY 2004. Samples have been collected from 62,864 sheep since April 1, 2003, of which results have been reported for 59,105 of which 209 were confirmed positive. During FY 2005, 33,137 samples were collected from 81 plants. There have been 130 NVSL confirmed positive cases (30 collected in FY 2004 and confirmed in FY 2005 and 100 collected and confirmed in FY 2005) in FY 2005. Face colors of these positives were 114 black, 14 mottled, 1 white and 1 unknown. The percent positive by face color is shown in the chart below.Scrapie TestingIn FY 2005, 35,845 animals have been tested for scrapie: 30,192 RSSS; 4,742 regulatory field cases; 772 regulatory third eyelid biopsies; 10 third eyelid validations; and 129 necropsy validations (chart 9).Animal IDAs of October 04, 2005, 103,580 sheep and goat premises have been assigned identification numbers in the Scrapie National Generic Database. Official eartags have been issued to 73,807 of these premises.*This number based on an adjusted 12 month interval to accommodate the 60 day period for setting up flock plans.http://www.usaha.org/committees/reports/2005/report-scr-2005.pdfDate: April 30, 2006 at 4:49 pm PST SCRAPIE USA UPDATE AS of March 31, 20062 NEW CASES IN GOAT, 82 INFECTED SOURCE FLOCKS, WITH 4 NEW INFECTED SOURCE FLOCKS IN MARCH, WITH 19 SCRAPIE INFECTED RSSS REPORTED BY NVSLhttp://www.aphis.usda.gov/vs/nahps/scrapie/monthly_report/monthly-report.htmlPublished online before print October 20, 2005Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0502296102 Medical SciencesA newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes( sheep prion transgenic mice )Annick Le Dur *, Vincent Béringue *, Olivier Andréoletti , Fabienne Reine *, Thanh Lan Laï *, Thierry Baron , Bjørn Bratberg ¶, Jean-Luc Vilotte , Pierre Sarradin **, Sylvie L. Benestad ¶, and Hubert Laude * *Virologie Immunologie Moléculaires and Génétique Biochimique et Cytogénétique, Institut National de la Recherche Agronomique, 78350 Jouy-en-Josas, France; Unité Mixte de Recherche, Institut National de la Recherche Agronomique-Ecole Nationale Vétérinaire de Toulouse, Interactions Hôte Agent Pathogène, 31066 Toulouse, France; Agence Française de Sécurité Sanitaire des Aliments, Unité Agents Transmissibles Non Conventionnels, 69364 Lyon, France; **Pathologie Infectieuse et Immunologie, Institut National de la Recherche Agronomique, 37380 Nouzilly, France; and ¶Department of Pathology, National Veterinary Institute, 0033 Oslo, NorwayEdited by Stanley B. Prusiner, University of California, San Francisco, CA, and approved September 12, 2005 (received for review March 21, 2005)Scrapie in small ruminants belongs to transmissible spongiform encephalopathies (TSEs), or prion diseases, a family of fatal neurodegenerative disorders that affect humans and animals and can transmit within and between species by ingestion or inoculation. Conversion of the host-encoded prion protein (PrP), normal cellular PrP (PrPc), into a misfolded form, abnormal PrP (PrPSc), plays a key role in TSE transmission and pathogenesis. The intensified surveillance of scrapie in the European Union, together with the improvement of PrPSc detection techniques, has led to the discovery of a growing number of so-called atypical scrapie cases. These include clinical Nor98 cases first identified in Norwegian sheep on the basis of unusual pathological and PrPSc molecular features and "cases" that produced discordant responses in the rapid tests currently applied to the large-scale random screening of slaughtered or fallen animals. Worryingly, a substantial proportion of such cases involved sheep with PrP genotypes known until now to confer natural resistance to conventional scrapie. Here we report that both Nor98 and discordant cases, including three sheep homozygous for the resistant PrPARR allele (A136R154R171), efficiently transmitted the disease to transgenic mice expressing ovine PrP, and that they shared unique biological and biochemical features upon propagation in mice. These observations support the view that a truly infectious TSE agent, unrecognized until recently, infects sheep and goat flocks and may have important implications in terms of scrapie control and public health.--------------------------------------------------------------------------------Author contributions: H.L. designed research; A.L.D., V.B., O.A., F.R., T.L.L., J.-L.V., and H.L. performed research; T.B., B.B., P.S., and S.L.B. contributed new reagents/analytic tools; V.B., O.A., and H.L. analyzed data; and H.L. wrote the paper.A.L.D. and V.B. contributed equally to this work.To whom correspondence should be addressed.Hubert Laude, E-mail: laude@jouy.inra.frwww.pnas.org/cgi/doi/10.1073/pnas.0502296102http://www.pnas.org/cgi/content/abstract/0502296102v112/10/76 AGRICULTURAL RESEARCH COUNCIL REPORT OF THE ADVISORY COMMITTE ON SCRAPIE Office Note CHAIRMAN: PROFESSOR PETER WILDYsnip...A The Present Position with respect to Scrapie A] The ProblemScrapie is a natural disease of sheep and goats. It is a slow and inexorably progressive degenerative disorder of the nervous system and it ia fatal. It is enzootic in the United Kingdom but not in all countries.The field problem has been reviewed by a MAFF working group (ARC 35/77). It is difficult to assess the incidence in Britain for a variety of reasons but the disease causes serious financial loss; it is estimated that it cost Swaledale breeders alone $l.7 M during the five years 1971-1975. A further inestimable loss arises from the closure of certain export markets, in particular those of the United States, to British sheep.It is clear that scrapie in sheep is important commercially and for that reason alone effective measures to control it should be devised as quickly as possible.Recently the question has again been brought up as to whether scrapie is transmissible to man. This has followed reports that the disease has been transmitted to primates. One particularly lurid speculation (Gajdusek 1977) conjectures that the agents of scrapie, kuru, Creutzfeldt-Jakob disease and transmissible encephalopathy of mink are varieties of a single "virus". The U.S. Department of Agriculture concluded that it could "no longer justify or permit scrapie-blood line and scrapie-exposed sheep and goats to be processed for human or animal food at slaughter or rendering plants" (ARC 84/77)" The problem is emphasised by the finding that some strains of scrapie produce lesions identical to the once which characterise the human dementias"Whether true or not. the hypothesis that these agents might be transmissible to man raises two considerations. First, the safety of laboratory personnel requires prompt attention. Second, action such as the "scorched meat" policy of USDA makes the solution of the acrapie problem urgent if the sheep industry is not to suffer grievously.snip...76/10.12/4.6http://www.bseinquiry.gov.uk/files/yb/1976/10/12004001.pdfLike lambs to the slaughter 31 March 2001 Debora MacKenzie Magazine issue 2284What if you can catch old-fashioned CJD by eating meat from a sheep infected with scrapie? FOUR years ago, Terry Singeltary watched his mother die horribly from a degenerative brain disease. Doctors told him it was Alzheimer's, but Singeltary was suspicious. The diagnosis didn't fit her violent symptoms, and he demanded an autopsy. It showed she had died of sporadic Creutzfeldt-Jakob disease.Most doctors believe that sCJD is caused by a prion protein deforming by chance into a killer. But Singeltary thinks otherwise. He is one of a number of campaigners who say that some sCJD, like the variant CJD related to BSE, is caused by eating meat from infected animals. Their suspicions have focused on sheep carrying scrapie, a BSE-like disease that is widespread in flocks across Europe and North America.Now scientists in France have stumbled across new evidence that adds weight to the campaigners' fears. To their complete surprise, the researchers found that one strain of scrapie causes the same brain damage in ...The complete article is 889 words long.full text;http://www.newscientist.com/article.ns?id=mg16922840.300Neurobiology Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt- Jakob disease: Implications for human healthCorinne Ida Lasmézas*,, Jean-Guy Fournier*, Virginie Nouvel*, Hermann Boe*, Domíníque Marcé*, François Lamoury*, Nicolas Kopp, Jean-Jacques Hauw§, James Ironside¶, Moira Bruce, Dominique Dormont*, and Jean-Philippe Deslys* * Commissariat à l'Energie Atomique, Service de Neurovirologie, Direction des Sciences du Vivant/Département de Recherche Medicale, Centre de Recherches du Service de Santé des Armées 60-68, Avenue du Général Leclerc, BP 6, 92 265 Fontenay-aux-Roses Cedex, France; Hôpital Neurologique Pierre Wertheimer, 59, Boulevard Pinel, 69003 Lyon, France; § Laboratoire de Neuropathologie, Hôpital de la Salpêtrière, 83, Boulevard de l'Hôpital, 75013 Paris, France; ¶ Creutzfeldt-Jakob Disease Surveillance Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, United Kingdom; and Institute for Animal Health, Neuropathogenesis Unit, West Mains Road, Edinburgh EH9 3JF, United KingdomEdited by D. Carleton Gajdusek, Centre National de la Recherche Scientifique, Gif-sur-Yvette, France, and approved December 7, 2000 (received for review October 16, 2000)AbstractThere is substantial scientific evidence to support the notion that bovine spongiform encephalopathy (BSE) has contaminated human beings, causing variant Creutzfeldt-Jakob disease (vCJD). This disease has raised concerns about the possibility of an iatrogenic secondary transmission to humans, because the biological properties of the primate-adapted BSE agent are unknown. We show that (i) BSE can be transmitted from primate to primate by intravenous route in 25 months, and (ii) an iatrogenic transmission of vCJD to humans could be readily recognized pathologically, whether it occurs by the central or peripheral route. Strain typing in mice demonstrates that the BSE agent adapts to macaques in the same way as it does to humans and confirms that the BSE agent is responsible for vCJD not only in the United Kingdom but also in France. The agent responsible for French iatrogenic growth hormone-linked CJD taken as a control is very different from vCJD but is similar to that found in one case of sporadic CJD and one sheep scrapie isolate. These data will be key in identifying the origin of human cases of prion disease, including accidental vCJD transmission, and could provide bases for vCJD risk assessment.http://www.pnas.org/cgi/content/full/041490898v1USDA CWD PROGRAMhttp://www.aphis.usda.gov/vs/nahps/cwd/USDA CWD MAP (slow to update)http://www.aphis.usda.gov/vs/nahps/cwd/cwd-distribution.htmlDRAFTWYOMING GAME AND FISH DEPARTMENTCHRONIC WASTING DISEASE MANAGEMENT PLANFebruary 17, 2006snip...5. Predicted population effects on free-ranging elk based on captive elk chronically exposed to the CWD prion. Forty-three female elk calves were trapped at the National Elk Refuge and transported to Sybille in February 2002. Elk were housed in pens, assumed to be environmentally contaminated with the CWD prion. Elk will be held throughout their lifetimes. Elk dying will be examined and cause of death determined. From these data, it will should be possible to model free-ranging elk mortality and population dynamics under extreme circumstances of CWD prion exposure and transmission. As of December 2005 (46 months post capture), 11 of 43 elk have died due to CWD. This compares to 100% mortality in less than 25 months in elk orally inoculated with different dosages of the CWD prion.REVISED DRAFThttp://gf.state.wy.us/downloads/pdf/CWD2005reviseddraft.pdfPrions in Skeletal Muscles of Deer with Chronic Wasting DiseaseRachel C. Angers,1* Shawn R. Browning,1*† Tanya S. Seward,2 Christina J. Sigurdson,4‡ Michael W. Miller,5 Edward A. Hoover,4 Glenn C. Telling1,2,3§1Department of Microbiology, Immunology and Molecular Genetics, 2Sanders Brown Center on Aging, 3Department of Neurology, University of Kentucky, Lexington, KY 40536, USA. 4Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. 5Colorado Division of Wildlife, Wildlife Research Center, Fort Collins, CO 80526, USA.*These authors contributed equally to this work.†Present address: Department of Infectology, Scripps Research Institute, 5353 Parkside Drive, RF-2, Jupiter, Florida, 33458, USA.‡Present address: Institute of Neuropathology, University of Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland.§To whom correspondence should be addressed: E-mail: gtell2@uky.eduPrions are transmissible proteinaceous agents of mammals that cause fatal neurodegenerative diseases of the central nervous system (CNS). The presence of infectivity in skeletal muscle of experimentally infected mice raised the possibility that dietary exposure to prions might occur through meat consumption (1). Chronic wasting disease (CWD), an enigmatic and contagious prion disease of North American cervids, is of particular concern. The emergence of CWD in an increasingly wide geographic area and the interspecies transmission of bovine spongiform encephalopathy (BSE) to humans as variant Creutzfeldt Jakob disease (vCJD) have raised concerns about zoonotic transmission of CWD.To test whether skeletal muscle of diseased cervids contained prion infectivity, Tg(CerPrP)1536 mice (2) expressing cervid prion protein (CerPrP), were inoculated intracerebrally with extracts prepared from the semitendinosus/semimembranosus muscle group of CWD-affected mule deer or from CWD-negative deer. The availability of CNS materials also afforded direct comparisons of prion infectivity in skeletal muscle and brain. All skeletal muscle extracts from CWD-affected deer induced progressive neurological dysfunction in Tg(CerPrP)1536 mice with mean incubation times ranging between 360 and ~490 d, whereas the incubation times of prions from the CNS ranged from ~230 to 280 d (Table 1). For each inoculation group, the diagnosis of prion disease was confirmed by the presence of PrPSc in the brains of multiple infected Tg(CerPrP)1536 mice (see supporting online material for examples). In contrast, skeletal muscle and brain material from CWD-negative deer failed to induce disease in Tg(CerPrP)1536 mice (Table 1) and PrPSc was not detected in the brains of sacrificed asymptomatic mice as late as 523 d after inoculation (supporting online material).Our results show that skeletal muscle as well as CNS tissue of deer with CWD contains infectious prions. Similar analyses of skeletal muscle BSE-affected cattle did not reveal high levels of prion infectivity (3). It will be important to assess the cellular location of PrPSc in muscle. Notably, while PrPSc has been detected in muscles of scrapie-affected sheep (4), previous studies failed to detect PrPSc by immunohistochemical analysis of skeletal muscle from deer with natural or experimental CWD (5, 6). Since the time of disease onset is inversely proportional to prion dose (7), the longer incubation times of prions from skeletal muscle extracts compared to matched brain samples indicated that prion titers were lower in muscle than in CNS where infectivity titers are known to reach high levels. Although possible effects of CWD strains or strain mixtures on these incubation times cannot be excluded, the variable 360 to ~490 d incubation times suggested a range of prion titers in skeletal muscles of CWD-affected deer. Muscle prion titers at the high end of the range produced the fastest incubation times that were ~30% longer than the incubation times of prions from the CNS of the same animal. Since all mice in each inoculation group developed disease, prion titers in muscle samples producing the longest incubation times were higher than the end point of the bioassay, defined as the infectious dose at which half the inoculated mice develop disease. Studies are in progress to accurately assess prion titers.While the risk of exposure to CWD infectivity following consumption of prions in muscle is mitigated by relatively inefficient prion transmission via the oral route (8), theseresults show that semitendinosus/semimembranosus muscle, which is likely to be consumed by humans, is a significant source of prion infectivity. Humans consuming or handling meat from CWD-infected deer are therefore at risk to prion exposure.References and Notes1. P. J. Bosque et al., Proc. Natl. Acad. Sci. U.S.A. 99, 3812 (2002).2. S. R. Browning et al., J. Virol. 78, 13345 (2004).3. A. Buschmann, M. H. Groschup, J. Infect. Dis. 192, 934 (2005).4. O. Andreoletti et al., Nat. Med. 10, 591 (2004).5. T. R. Spraker et al., Vet. Pathol. 39, 110 (2002).6. A. N. Hamir, J. M. Miller, R. C. Cutlip, Vet. Pathol. 41, 78 (2004).7. S. B. Prusiner et al., Biochemistry 21, 4883 (1980).8. M. Prinz et al., Am. J. Pathol. 162, 1103 (2003).9. This work was supported by grants from the U.S. Public Health Service 2RO1 NS040334-04 from the National Institute of Neurological Disorders and Stroke and N01-AI-25491 from the National Institute of Allergy and Infectious Diseases.Supporting Online Materialwww.sciencemag.org/Materials and MethodsFig. S121 November 2005; accepted 13 January 2006 Published online 26 January 2006; 10.1126/science.1122864 Include this information when citing this paper.Table 1. Incubation times following inoculation of Tg(CerPrP)1536 mice with prions from skeletal muscle and brain samples of CWD-affected deer.Inocula Incubation time, mean d ± SEM (n/n0)*Skeletal muscle BrainCWD-affected deerH92 360 ± 2 d (6/6) 283 ± 7 d (6/6)33968 367 ± 9 d (8/8) 278 ± 11 d (6/6)5941 427 ± 18 d (7/7)D10 483 ± 8 d (8/8) 231 ± 17 d (7/7)D08 492 ± 4 d (7/7)Averages 426 d 264 dNon-diseased deerFPS 6.98 >523 d (0/6)FPS 9.98 >454 d (0/7) >454 d (0/6)None >490 d (0/6)PBS >589 d (0/5)*The number of mice developing prion disease divided by the original number of inoculated mice is shown in parentheses. Mice dying of intercurrent illnesses were excluded.http://www.sciencemag.org/www.sciencemag.org/Supporting Online Material forPrions in Skeletal Muscles of Deer with Chronic Wasting DiseaseRachel C. Angers, Shawn R. Browning, Tanya S. Seward, Christina J. Sigurdson,Michael W. Miller, Edward A. Hoover, Glenn C. Telling§§To whom correspondence should be addressed: E-mail: gtell2@uky.eduPublished 26 January 2006 on Science ExpressDOI: 10.1126/science.1122864This PDF file includes:Materials and MethodsFig. S1Supporting Online MaterialsMaterials and MethodsHomogenates of semitendinosus/semimembranosus muscle (10% w/v in phosphatebuffered saline) were prepared from five emaciated and somnolent mule deer, naturallyinfected with CWD at the Colorado Division of Wildlife, Wildlife Research Center.These deer were identified as D10, D08, 33968, H92, and 5941. CWD infection wasconfirmed in all cases by the presence of histologic lesions in the brain includingspongiform degeneration of the perikaryon, the immunohistochemical detection ofdisease-associated PrP in brain and tonsil, or by immunoblotting of protease-resistant,disease associated PrP (CerPrPSc). Semitendinosus/semimembranosus muscle was alsoobtained from two asymptomatic, mock inoculated deer, referred to as FPS 6.68 and 9.98,that originated from a CWD non-endemic area and which were held indoors at ColoradoState University from ten days of age. These control deer were confirmed negative forCWD by histopathological and immunohistochemical analysis of brain tissue at autopsy.The utmost care was taken to avoid inclusion of obvious nervous tissue when musclebiopsies were prepared and to ensure that contamination of skeletal muscle samples withCNS tissue did not occur. Fresh, single-use instruments were used to collect each samplebiopsy and a central piece from each sample was prepared with fresh, disposableinstruments to further isolate muscle tissue for inoculum preparation. Brain samples fortransmission were prepared separately from muscle as additional insurance against crosscontamination.1Groups of anesthetized Tg(CerPrP)1536 mice were inoculated intracerebrally with 30 µlof 1 % skeletal muscle or brain extracts prepared in phosphate buffered saline (PBS).Inoculated Tg(CerPrP) mice were diagnosed with prion disease following the progressivedevelopment of at least three neurologic symptoms including truncal ataxia, ‘plastic’ tail,loss of extensor reflex, difficultly righting, and slowed movement. The time frominoculation to the onset of clinical signs is referred to as the incubation time.For PrP analysis in brain extracts of Tg(CerPrP)1536 mice, 10 % homogenates preparedin PBS were either untreated (-) or treated (+) with 40 µg/ml proteinase K (PK) for onehour at 37oC in the presence of 2% sarkosyl. Proteins were separated by sodium dodecylsulfate polyacrylamide gel electrophoresis, analyzed by immunoblotting using anti PrPmonoclonal antibody 6H4 (Prionics AG, Switzerland), incubated with appropriatesecondary antibody, developed using ECL-plus detection (Amersham), and analyzedusing a FLA-5000 scanner (Fuji).2Fig. S1PrP in brain extracts from representative Tg(CerPrP)1536 mice receiving muscle or CNStissue inocula from CWD-affected or CWD-negative deer. Extracts were either treated(+) or untreated (-) with proteinase K (PK) as indicated. The positions of proteinmolecular weight markers at 21.3, 28.7, 33.5 kDa (from bottom to top) are shown to theleft of the immunoblot.3http://www.sciencemag.org/Chronic Wasting Disease and Potential Transmission to HumansErmias D. Belay,* Ryan A. Maddox,* Elizabeth S. Williams,† Michael W. Miller,‡ Pierluigi Gambetti,§ and Lawrence B. Schonberger* *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †University of Wyoming, Laramie, Wyoming, USA; ‡Colorado Division of Wildlife, Fort Collins, Colorado, USA; and §Case Western Reserve University, Cleveland, Ohio, USASuggested citation for this article: Belay ED, Maddox RA, Williams ES, Miller MW, Gambetti P, Schonberger LB. Chronic wasting disease and potential transmission to humans. Emerg Infect Dis [serial on the Internet]. 2004 Jun [date cited]. Available from:http://www.cdc.gov/ncidod/EID/vol10no6/03-1082.htmhttp://www.cdc.gov/ncidod/EID/vol10no6/03-1082.htmResearchEnvironmental Sources of Prion Transmission in Mule Deer Michael W. Miller,* Elizabeth S. Williams,† N. Thompson Hobbs,‡ and Lisa L. Wolfe* *Colorado Division of Wildlife, Fort Collins, Colorado, USA; †University of Wyoming, Laramie, Wyoming, USA; and ‡Colorado State University, Fort Collins, Colorado, USASuggested citation for this article: Miller MW, Williams ES, Hobbs NT, Wolfe LL. Environmental sources of prion transmission in mule deer. Emerg Infect Dis [serial on the Internet]. 2004 Jun [date cited]. Available from: http://www.cdc.gov/ncidod/EID/vol10no6/04-0010.htmhttp://www.cdc.gov/ncidod/EID/vol10no6/04-0010.htmATYPICAL TSEs in USA CATTLE AND SHEEP ?http://www.bseinquiry.gov.uk/files/sc/seac17/tab03.pdfUKBSEnvCJD only theory Singeltary et al 2006 (please note, et al in this term means all victims and familes of the sporadic CJD that are still looking for answers. ...TSS)http://www.microbes.info/forums/index.php?act=Attach&type=post&id=13http://www.microbes.info/forums/index.php?showtopic=306NEW STRAIN OF TSE USA CATTLE OR JUST INCOMPETENCE IN TESTING???http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdfCJD WATCHhttp://www.fortunecity.com/healthclub/cpr/349/part1cjd.htmCJD WATCH MESSAGE BOARDhttp://disc.server.com/Indices/167318.htmlTerry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518posted by Terry S. Singeltary Sr. 5:57 PM4 Comments: Terry S. Singeltary Sr. said...##################### Bovine Spongiform Encephalopathy #####################Subject: MAD COW FEED BAN WARNING LETTER ISSUED MAY 17, 2006Date: June 27, 2006 at 7:42 am PSTPublic Health Service Food and Drug AdministrationNew Orleans District 297 Plus Park Blvd. Nashville, TN 37217Telephone: 615-781-5380 Fax: 615-781-5391May 17, 2006WARNING LETTER NO. 2006-NOL-06FEDERAL EXPRESS OVERNIGHT DELIVERYMr. William Shirley, Jr., Owner Louisiana.DBA Riegel By-Products 2621 State Street Dallas, Texas 75204Dear Mr. Shirley:On February 12, 17, 21, and 22, 2006, a U.S. Food & Drug Administration (FDA) investigator inspected your rendering plant, located at 509 Fortson Street, Shreveport, Louisiana. The inspection revealed significant deviations from the requirements set forth in Title 21, Code of Federal Regulations, Part 589.2000 [21 CFR 589.2000], Animal Proteins Prohibited in Ruminant Feed. This regulation is intended to prevent the establishment and amplification of Bovine Spongiform Encephalopathy (BSE). You failed to follow the requirements of this regulation; products being manufactured and distributed by your facility are misbranded within the meaning of Section 403(a)(1) [21 USC 343(a)(1)] of the Federal Food, Drug, and Cosmetic Act (the Act).Our investigation found you failed to provide measures, including sufficient written procedures, to prevent commingling or cross-contamination and to maintain sufficient written procedures [21 CFR 589.2000(e)] because:You failed to use clean-out procedures or other means adequate to prevent carryover of protein derived from mammalian tissues into animal protein or feeds which may be used for ruminants. For example, your facility uses the same equipment to process mammalian and poultry tissues. However, you use only hot water to clean the cookers between processing tissues from each species. You do not clean the auger, hammer mill, grinder, and spouts after processing mammalian tissues.You failed to maintain written procedures specifying the clean-out procedures or other means to prevent carryover of protein derived from mammalian tissues into feeds which may be used for ruminants.As a result . the poultry meal you manufacture may contain protein derived from mammalian tissues prohibited in ruminant feed. Pursuant to 21 CFR 589.2000(e)(1)(i), any products containing or may contain protein derived from mammalian tissues must be labeled, "Do not feed to cattle or other ruminants." Since you failed to label a product which may contain protein derived from mammalian tissues with the required cautionary statement. the poultry meal is misbranded under Section 403(a)(1) [21 USC 343(a)(1)] of the Act.This letter is not intended as an all-inclusive list of violations at your facility. As a manufacturer of materials intended for animal feed use, you are responsible for ensuring your overall operation and the products you manufacture and distribute are in compliance with the law. You should take prompt action to correct these violations, and you should establish a system whereby violations do not recur. Failure to promptly correct these violations may result in regulatory action, such as seizure and/or injunction, without further notice.You should notify this office in writing within 15 working days of receiving this letter, outlining the specific steps you have taken to bring your firm into compliance with the law. Your response should include an explanation of each step taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within 15 working days, state the reason for the delay and the date by which the corrections will be completed. Include copies of any available documentation demonstrating corrections have been made.Your reply should be directed to Mark W. Rivero, Compliance Officer, U.S. Food and Drug Administration, 2424 Edenborn Avenue, Suite 410, Metairie, Louisiana 70001. If you have questions regarding any issue in this letter, please contact Mr. Rivero at (504) 219-8818, extension 103.Sincerely,/SCarol S. Sanchez Acting District Director New Orleans Districthttp://www.fda.gov/foi/warning_letters/g5883d.htmAHH, with all the bad news about FDA et al on there lack of enforcement, I would have expected a token mad cow feed ban warning letter or two to pop up now. what would really be interesting would be to see all violations of the mad cow feed ban, large and small, from all states. ...tss#################### https://lists.aegee.org/bse-l.html ####################Subject: [Docket No. 03-025IFA] SRMs and Non-Ambulatory disabled cattle[TSS] Date: October 6, 2005 at 2:28 pm PST[Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirement for the Disposition of Non-Ambulatory Disabled Cattle03-025IFA 03-025IFA-2 Terry S. SingeltaryPage 1 of 17From: Terry S. Singeltary Sr. [flounder9@verizon.net]Sent: Thursday, September 08, 2005 6:17 PMTo: fsis.regulationscomments@fsis.usda.govSubject: [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirementsfor the Disposition of Non-Ambulatory Disabled CattleGreetings FSIS,I would kindly like to submit the following to [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food andRequirements for the Disposition of Non-Ambulatory Disabled CattleTHE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled CattleBroken bones and such may be the first signs of a sub clinical BSE/TSE Non-Ambulatory Disabled Cattle ;SUB CLINICAL PRION INFECTIONMRC-43-00Issued: Monday, 28 August 2000NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT RESEARCHFINDINGS RELEVANT TO CJD AND BSETerry S. Singeltary Sr.P.O. Box 42Bacliff, Texas USA 775189/13/2005http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdfTSS6:48 PM Terry S. Singeltary Sr. said... ##################### Bovine Spongiform Encephalopathy #####################CJD WATCH MESSAGE BOARD TSS Monthly Creutzfeldt Jakob disease statistics July 3, 2006 Mon Jul 3, 2006 11:47 68.238.110.55Date: July 03, 2006 Time: 15:15 Monthly Creutzfeldt Jakob disease statistics publishedThe Department of Health is today issuing the latest information about the numbers of known cases of Creutzfeldt Jakob disease. This includes cases of variant Creutzfeldt Jakob disease (vCJD) - the form of the disease thought to be linked to BSE. The position is as follows:Definite and probable CJD cases in the UK:As at 30 June 2006Summary of vCJD casesDeathsDeaths from definite vCJD (confirmed): 111Deaths from probable vCJD (without neuropathological confirmation): 44Deaths from probable vCJD (neuropathological confirmation pending): 1Number of deaths from definite or probable vCJD (as above): 156AliveNumber of probable vCJD cases still alive: 5Total number of definite or probable vCJD (dead and alive): 161The next table will be published on Monday 7th August 2006Referrals: a simple count of all the cases which have been referred to the National CJD Surveillance Unit for further investigation in the year in question. CJD may be no more than suspected; about half the cases referred in the past have turned out not to be CJD. Cases are notified to the Unit from a variety of sources including neurologists, neuropathologists, neurophysiologists, general physicians, psychiatrists, electroencephalogram (EEG) departments etc. As a safety net, death certificates coded under the specific rubrics 046.1 and 331.9 in the 9th ICD Revisions are obtained from the Office for National Statistics in England and Wales, the General Register Office for Scotland and the General Register Office for Northern Ireland.Deaths: All columns show the number of deaths that have occurred in definite and probable cases of all types of CJD and GSS in the year shown. The figures include both cases referred to the Unit for investigation while the patient was still alive and those where CJD was only discovered post mortem (including a few cases picked up by the Unit from death certificates). There is therefore no read across from these columns to the referrals column. The figures will be subject to retrospective adjustment as diagnoses are confirmed.Definite cases: this refers to the diagnostic status of cases. In definite cases the diagnosis will have been pathologically confirmed, in most cases by post mortem examination of brain tissue (rarely it may be possible to establish a definite diagnosis by brain biopsy while the patient is still alive).Probable vCJD cases: are those who fulfil the 'probable' criteria set out in the Annex and are either still alive, or have died and await post mortem pathological confirmation. Those still alive will always be shown within the current year's figures.Sporadic: Classic CJD cases with typical EEG and brain pathology. Sporadic cases appear to occur spontaneously with no identifiable cause and account for 85% of all cases.Probable sporadic: Cases with a history of rapidly progressive dementia, typical EEG and at least two of the following clinical features; myoclonus, visual or cerebellar signs, pyramidal/extrapyramidalsigns or akinetic mutism.Iatrogenic: where infection with classic CJD has occurred accidentally as the result of a medical procedure. All UK cases have resulted from treatment with human derived pituitary growth hormones or from grafts using dura mater (a membrane lining the skull).Familial: cases occurring in families associated with mutations in the PrP gene (10 - 15% of cases).GSS: Gerstmann-Straussler-Scheinker syndrome - an exceedingly rare inherited autosomal dominant disease, typified by chronic progressive ataxia and terminal dementia. The clinical duration is from 2 to 10 years, much longer than for CJD.vCJD: Variant CJD, the hitherto unrecognised variant of CJD discovered by the National CJD Surveillance Unit and reported in The Lancet on 6 April 1996. This is characterised clinically by a progressive neuropsychiatric disorder leading to ataxia, dementia and myoclonus (or chorea) without the typical EEG appearance of CJD. Neuropathology shows marked spongiform change and extensive florid plaques throughout the brain.Definite vCJD cases still alive: These will be cases where the diagnosis has been pathologically confirmed (by brain biopsy).Related linksDownload cjd annual stats (PDF, 145K)Notes to editorANNEXDIAGNOSTIC CRITERIA FOR VARIANT CJDI A) PROGRESSIVE NEUROPSYCHIATRIC DISORDERB) DURATION OF ILLNESS > 6 MONTHSC) ROUTINE INVESTIGATIONS DO NOT SUGGEST AN ALTERNATIVE DIAGNOSISD) NO HISTORY OF POTENTIAL IATROGENIC EXPOSUREII A) EARLY PSYCHIATRIC SYMPTOMS *B) PERSISTENT PAINFUL SENSORY SYMPTOMS **C) ATAXIAD) MYOCLONUS OR CHOREA OR DYSTONIAE) DEMENTIAIII A) EEG DOES NOT SHOW THE TYPICAL APPEARANCE OF SPORADICCJD *** (OR NO EEG PERFORMED)B) BILATERAL PULVINAR HIGH SIGNAL ON MRI SCANIV A) POSITIVE TONSIL BIOPSYDEFINITE: IA (PROGRESSIVE NEUROPSYCHIATRIC DISORDER) and NEUROPATHOLOGICAL CONFIRMATION OF vCJD ****PROBABLE: I and 4/5 OF II and III A and III Bor I and IV A* depression, anxiety, apathy, withdrawal, delusions.** this includes both frank pain and/ or unpleasant dysaesthesia*** generalised triphasic periodic complexes at approximately one per second****spongiform change and extensive PrP deposition with florid plaques, throughout the cerebrum and cerebellum.http://www.wired-gov.net/WGLaunch.aspx?ARTCL=39920TOTAL CASES OF SPORADIC CJD (DEATHS)http://www.eurocjd.ed.ac.uk/sporadic.htmTOTAL CASES OF FAMILIAL/GENETIC CJD AND IATROGENIC CJD DEATHS TO 31 MARCH 2006http://www.eurocjd.ed.ac.uk/genetic.htmCJD USA(please note steady increase in sporadic cjd from 1997 to 2004 with steady increase in type 'UNKNOWN' CJD? also, seems like they could come up with a better, more readable chart. ...TSS)http://www.cjdsurveillance.com/resources-casereport.htmlHUMAN and ANIMAL TSE Classifications i.e. mad cow disease and the UKBSEnvCJD only theoryTSEs have been rampant in the USA for decades in many species, and they all have been rendered and fed back to animals for human/animal consumption. I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2005. With all the science to date refuting it, to continue to validate this myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, surgical, blood, medical, cosmetics etc. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Tranmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route. This would further have to be broken down to strain of species and then the route of transmission would further have to be broken down. Accumulation and Transmission are key to the threshold from subclinical to clinical disease, and key to all this, is to stop the amplification and transmission of this agent, the spreading of, no matter what strain. BUT, to continue with this myth that the U.K. strain of BSE one strain in cows, and the nv/v CJD, one strain in humans, and that all the rest of human TSE is one single strain i.e. sporadic CJD (when to date there are 6 different phenotypes of sCJD), and that no other animal TSE transmits to humans, to continue with this masquerade will only continue to spread, expose, and kill, who knows how many more in the years and decades to come. ONE was enough for me, My Mom, hvCJD, DOD 12/14/97 confirmed, which is nothing more than another mans name added to CJD, like CJD itself, Jakob and Creutzfeldt, or Gerstmann-Straussler-Scheinker syndrome, just another CJD or human TSE, named after another human. WE are only kidding ourselves with the current diagnostic criteria for human and animal TSE, especially differentiating between the nvCJD vs the sporadic CJD strains and then the GSS strains and also the FFI fatal familial insomnia strains or the ones that mimics one or the other of those TSE? Tissue infectivity and strain typing of the many variants of the human and animal TSEs are paramount in all variants of all TSE. There must be a proper classification that will differentiate between all these human TSE in order to do this. With the CDI and other more sensitive testing coming about, I only hope that my proposal will some day be taken seriously. ...TSSCoexistence of multiple PrPSc types in individuals withCreutzfeldt-Jakob diseaseMagdalini Polymenidou, Katharina Stoeck, Markus Glatzel, Martin Vey, Anne Bellon, and Adriano AguzziSummaryBackground The molecular typing of sporadic Creutzfeldt-Jakob disease (CJD) is based on the size and glycoform ratio of protease-resistant prion protein (PrPSc), and on PRNP haplotype. On digestion with proteinase K, type 1 and type 2 PrPSc display unglycosylated core fragments of 21 kDa and 19 kDa, resulting from cleavage around amino acids 82 and 97, respectively.Methods We generated anti-PrP monoclonal antibodies to epitopes immediately preceding the differential proteinase K cleavage sites. These antibodies, which were designated POM2 and POM12, recognise type 1, but not type 2, PrPSc.Findings We studied 114 brain samples from 70 patients with sporadic CJD and three patients with variant CJD.Every patient classified as CJD type 2, and all variant CJD patients, showed POM2/POM12 reactivity in the cerebellum and other PrPSc-rich brain areas, with a typical PrPSc type 1 migration pattern.Interpretation The regular coexistence of multiple PrPSc types in patients with CJD casts doubts on the validity of electrophoretic PrPSc mobilities as surrogates for prion strains, and questions the rational basis of current CJDclassifications. ...http://neurology.thelancet.comJ Neuropsychiatry Clin Neurosci 17:489-495, November 2005 doi: 10.1176/appi.neuropsych.17.4.489 © 2005 American Psychiatric Publishing, Inc.Psychiatric Manifestations of Creutzfeldt-Jakob Disease: A 25-Year Analysis Christopher A. Wall, M.D., Teresa A. Rummans, M.D., Allen J. Aksamit, M.D., Lois E. Krahn, M.D. and V. Shane Pankratz, Ph.D. Received April 20, 2004; revised September 9, 2004; accepted September 13, 2004. From the Mayo Clinic, Department of Psychiatry and Psychology, Rochester, Minnesota; Mayo Clinic, Department of Neurology, Rochester, Minnesota. Address correspondence to Dr. Wall, Mayo Clinic, Department of Psychiatry and Psychology, Mayo Building-W11A, 200 First St., SW, Rochester, MN 55905; wall.chris@mayo.edu (E-mail).This study characterizes the type and timing of psychiatric manifestations in sporadic Creutzfeldt-Jakob disease (sCJD). Historically, sCJD has been characterized by prominent neurological symptoms, while the variant form (vCJD) is described as primarily psychiatric in presentation and course: A retrospective review of 126 sCJD patients evaluated at the Mayo Clinic from 1976-2001 was conducted. Cases were reviewed for symptoms of depression, anxiety, psychosis, behavior dyscontrol, sleep disturbances, and neurological signs during the disease course. Eighty percent of the cases demonstrated psychiatric symptoms within the first 100 days of illness, with 26% occurring at presentation. The most commonly reported symptoms in this population included sleep disturbances, psychotic symptoms, and depression. Psychiatric manifestations are an early and prominent feature of sporadic CJD, often occurring prior to formal diagnosis.snip...CONCLUSIONSHistorically, psychiatric manifestations have been described as a relatively infrequent occurrence in the sporadic form of creutzfeldt-Jakob disease. However, our findings suggest otherwise. In this study, a vast majority of the cases were noted to have at least one psychiatric symptom during the course of illness, with nearly one-quarter occurring in the prodromal or presenting phase of the illness. After comparing the frequency of neuropsychiatric symptoms in sporadic CJD to studies describing the variant form of CJD, we found that there are fewer clinical differences than previously reported.5-7 While the age of patients with vCJD presentation is significantly younger and the course of illness is longer, the type and timing of psychiatric manifestations appear similar between these two diseases. ...snip...http://neuro.psychiatryonline.org/cgi/content/abstract/17/4/489Personal Communication-------- Original Message --------Subject: re-BSE prions propagate aseither variant CJD-like or sporadic CJD Date: Thu, 28 Nov 2002 10:23:43-0000 From: "Asante, Emmanuel A" To: "'flounder@wt.net'"Dear Terry,I have been asked by Professor Collinge to respond to your request. I ama Senior Scientist in the MRC Prion Unit and the lead author on thepaper. I have attached a pdf copy of the paper for your attention. Thankyou for your interest in the paper.In respect of your first question, the simple answer is, yes. As youwill find in the paper, we have managed to associate the alternatephenotype to type 2 PrPSc, the commonest sporadic CJD.It is too early to be able to claim any further sub-classification inrespect of Heidenhain variant CJD or Vicky Rimmer's version. It willtake further studies, which are on-going, to establish if there aresub-types to our initial finding which we are now reporting. The mainpoint of the paper is that, as well as leading to the expected newvariant CJD phenotype, BSE transmission to the 129-methionine genotypecan lead to an alternate phenotype which is indistinguishable from type2 PrPSc.I hope reading the paper will enlighten you more on the subject. If Ican be of any further assistance please to not hesitate to ask. Best wishes.Emmanuel Asante<> ____________________________________Dr. Emmanuel A Asante MRC Prion Unit & Neurogenetics Dept. ImperialCollege School of Medicine (St. Mary's) Norfolk Place, LONDON W2 1PGTel: +44 (0)20 7594 3794 Fax: +44 (0)20 7706 3272 email:e.asante@ic.ac.uk (until 9/12/02)New e-mail: e.asante@prion.ucl.ac.uk (active from now)____________________________________Full Text Diagnosis and Reporting of Creutzfeldt-Jakob Disease Singeltary, Sr et al. JAMA.2001; 285: 733-734http://jama.ama-assn.org/cgi/content/full/285/6/733?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=dignosing+and+reporting+creutzfeldt+jakob+disease&searchid=1048865596978_1528&stored_search=&FIRSTINDEX=0&journalcode=jamaTSS#################### https://lists.aegee.org/bse-l.html ####################6:53 PM Terry S. Singeltary Sr. said... Latest Information (as of July 4, 2006 - 17:30 EST) Final test results have confirmed bovine spongiform encephalopathy (BSE) in a mature cross-bred beef cow from Manitoba. The Canadian Food Inspection Agency (CFIA) is conducting a comprehensive investigation. Officials have confirmed the animal was purchased by the owner as part of an assembled group of cattle in 1992. This means that the animal was at least 15 years of age and would have been born well before the 1997 introduction of Canada’s feed ban. As a priority, investigators are attempting to locate the birth farm, which will provide the basis needed to identify the animal’s herdmates and feed to which it may have been exposed at a young age. Given the animal’s age, investigative efforts may be constrained by few surviving animals and limited sources of information, such as detailed records. A calf born to the affected animal in 2004 is also being traced.---------------------------------------------------------------------------- ----http://www.inspection.gc.ca/english/anima/heasan/disemala/bseesb/situatione.shtmlTSS6:55 PM Terry S. Singeltary Sr. said... ##################### Bovine Spongiform Encephalopathy #####################Subject: MAD COW FEED RECALLS ENFORCEMENT REPORT FOR AUGUST 9, 2006 KY, LA, MS, AL, GA, AND TN 11,000+ TONS Date: August 16, 2006 at 9:19 am PSTRECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINE - CLASS II ______________________________ PRODUCT Bulk custom made dairy feed, Recall # V-115-6 CODE None RECALLING FIRM/MANUFACTURER Hiseville Feed & Seed Co., Hiseville, KY, by telephone and letter on or about July 14, 2006. FDA initiated recall is ongoing. REASON Custom made feeds contain ingredient called Pro-Lak which may contain ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE Approximately 2,223 tons DISTRIBUTION KY______________________________ PRODUCT Bulk custom made dairy feed, Recall # V-116-6 CODE None RECALLING FIRM/MANUFACTURER Rips Farm Center, Tollesboro, KY, by telephone and letter on July 14, 2006. FDA initiated recall is ongoing. REASON Custom made feeds contain ingredient called Pro-Lak which may contain ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 1,220 tons DISTRIBUTION KY______________________________ PRODUCT Bulk custom made dairy feed, Recall # V-117-6 CODE None RECALLING FIRM/MANUFACTURER Kentwood Co-op, Kentwood, LA, by telephone on June 27, 2006. FDA initiated recall is completed. REASON Possible contamination of animal feed ingredients, including ingredients that are used in feed for dairy animals, with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 40 tons DISTRIBUTION LA and MS______________________________ PRODUCT Bulk Dairy Feed, Recall V-118-6 CODE None RECALLING FIRM/MANUFACTURER Cal Maine Foods, Inc., Edwards, MS, by telephone on June 26, 2006. FDA initiated recall is complete. REASON Possible contamination of animal feed ingredients, including ingredients that are used in feed for dairy animals, with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 7,150 tons DISTRIBUTION MS______________________________ PRODUCT Bulk custom dairy pre-mixes, Recall # V-119-6 CODE None RECALLING FIRM/MANUFACTURER Walthall County Co-op, Tylertown, MS, by telephone on June 26, 2006. Firm initiated recall is complete. REASON Possible contamination of dairy animal feeds with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 87 tons DISTRIBUTION MS______________________________ PRODUCT Bulk custom dairy pre-mixes, Recall # V-120-6 CODE None RECALLING FIRM/MANUFACTURER Ware Milling Inc., Houston, MS, by telephone on June 23, 2006. Firm initiated recall is complete. REASON Possible contamination of dairy animal feeds with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 350 tons DISTRIBUTION AL and MS______________________________ PRODUCT a) Tucker Milling, LLC Tm 32% Sinking Fish Grower, #2680-Pellet, 50 lb. bags, Recall # V-121-6; b) Tucker Milling, LLC #31120, Game Bird Breeder Pellet, 50 lb. bags, Recall # V-122-6; c) Tucker Milling, LLC #31232 Game Bird Grower, 50 lb. bags, Recall # V-123-6; d) Tucker Milling, LLC 31227-Crumble, Game Bird Starter, BMD Medicated, 50 lb bags, Recall # V-124-6; e) Tucker Milling, LLC #31120, Game Bird Breeder, 50 lb bags, Recall # V-125-6; f) Tucker Milling, LLC #30230, 30 % Turkey Starter, 50 lb bags, Recall # V-126-6; g) Tucker Milling, LLC #30116, TM Broiler Finisher, 50 lb bags, Recall # V-127-6 CODE All products manufactured from 02/01/2005 until 06/20/2006 RECALLING FIRM/MANUFACTURER Recalling Firm: Tucker Milling LLC, Guntersville, AL, by telephone and visit on June 20, 2006, and by letter on June 23, 2006. Manufacturer: H. J. Baker and Brothers Inc., Stamford, CT. Firm initiated recall is ongoing. REASON Poultry and fish feeds which were possibly contaminated with ruminant based protein were not labeled as "Do not feed to ruminants". VOLUME OF PRODUCT IN COMMERCE 7,541-50 lb bags DISTRIBUTION AL, GA, MS, and TNEND OF ENFORCEMENT REPORT FOR AUGUST 9, 2006###http://www.fda.gov/bbs/topics/ENFORCE/2006/ENF00964.htmlGOTTA LOVE THOSE FDA/USDA TRIPLE BSE FIREWALLS. ...TSSWE know now, and we knew decades ago, that 5.5 grams of suspect feed in TEXAS was enough to kill 100 cows ;http://www.fda.gov/bbs/topics/NEWS/2001/NEW00752.htmlNOT TO FORGET THE TEXAS MAD COW THAT DID GET AWAY ;http://www.fda.gov/bbs/topics/news/2004/NEW01061.htmllook at the table and you'll see that as little as 1 mg (or 0.001 gm) caused 7% (1 of 14) of the cows to come down with BSE;Risk of oral infection with bovine spongiform encephalopathy agent in primatesCorinne Ida Lasmézas, Emmanuel Comoy, Stephen Hawkins, Christian Herzog, Franck Mouthon, Timm Konold, Frédéric Auvré, Evelyne Correia, Nathalie Lescoutra-Etchegaray, Nicole Salès, Gerald Wells, Paul Brown, Jean-Philippe Deslys Summary The uncertain extent of human exposure to bovine spongiform encephalopathy (BSE)--which can lead to variant Creutzfeldt-Jakob disease (vCJD)--is compounded by incomplete knowledge about the efficiency of oral infection and the magnitude of any bovine-to-human biological barrier to transmission. We therefore investigated oral transmission of BSE to non-human primates. We gave two macaques a 5 g oral dose of brain homogenate from a BSE-infected cow. One macaque developed vCJD-like neurological disease 60 months after exposure, whereas the other remained free of disease at 76 months. On the basis of these findings and data from other studies, we made a preliminary estimate of the food exposure risk for man, which provides additional assurance that existing public health measures can prevent transmission of BSE to man.snip...BSE bovine brain inoculum100 g 10 g 5 g 1 g 100 mg 10 mg 1 mg 0·1 mg 0·01 mgPrimate (oral route)* 1/2 (50%)Cattle (oral route)* 10/10 (100%) 7/9 (78%) 7/10 (70%) 3/15 (20%) 1/15 (7%) 1/15 (7%)RIII mice (ic ip route)* 17/18 (94%) 15/17 (88%) 1/14 (7%)PrPres biochemical detectionThe comparison is made on the basis of calibration of the bovine inoculum used in our study with primates against a bovine brain inoculum with a similar PrPres concentration that wasinoculated into mice and cattle.8 *Data are number of animals positive/number of animals surviving at the time of clinical onset of disease in the first positive animal (%). The accuracy ofbioassays is generally judged to be about plus or minus 1 log. ic ip=intracerebral and intraperitoneal.Table 1: Comparison of transmission rates in primates and cattle infected orally with similar BSE brain inoculaPublished online January 27, 2005http://www.thelancet.com/journal/journal.isaIt is clear that the designing scientists mustalso have shared Mr Bradley’s surprise at the results because all the doselevels right down to 1 gram triggered infection.http://www.bseinquiry.gov.uk/files/ws/s145d.pdf26. It also appears to me that Mr Bradley’s answer (that it would take less than say 100grams) was probably given with the benefit of hindsight; particularly if oneconsiders that later in the same answer Mr Bradley expresses his surprise that itcould take as little of 1 gram of brain to cause BSE by the oral route within thesame species. This information did not become available until the "attack rate"experiment had been completed in 1995/96. This was a titration experimentdesigned to ascertain the infective dose. A range of dosages was used to ensurethat the actual result was within both a lower and an upper limit within the studyand the designing scientists would not have expected all the dose levels to triggerinfection. The dose ranges chosen by the most informed scientists at that timeranged from 1 gram to three times one hundred grams. It is clear that the designingscientists must have also shared Mr Bradley’s surprise at the results because all thedose levels right down to 1 gram triggered infection.http://www.bseinquiry.gov.uk/files/ws/s147f.pdfRe: BSE .1 GRAM LETHAL NEW STUDY SAYS via W.H.O. Dr Maura Ricketts[BBC radio 4 FARM news]http://www.maddeer.org/audio/BBC4farmingtoday2_1_03.ramhttp://www.fda.gov/ohrms/dockets/ac/03/slides/3923s1_OPH.htm2) Infectious dose:To cattle: 1 gram of infected brain material (by oral ingestion)http://www.inspection.gc.ca/english/sci/bio/bseesbe.shtmlTerry S. Singeltary Sr.P.O. Box 42Bacliff, Texas USA 77518[Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirement for the Disposition of Non-Ambulatory Disabled Cattle03-025IFA 03-025IFA-2 Terry S. SingeltaryPage 1 of 17From: Terry S. Singeltary Sr. [flounder9@verizon.net]Sent: Thursday, September 08, 2005 6:17 PMTo: fsis.regulationscomments@fsis.usda.govSubject: [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirementsfor the Disposition of Non-Ambulatory Disabled CattleGreetings FSIS,I would kindly like to submit the following to [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food andRequirements for the Disposition of Non-Ambulatory Disabled CattleTHE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled CattleBroken bones and such may be the first signs of a sub clinical BSE/TSE Non-Ambulatory Disabled Cattle ;SUB CLINICAL PRION INFECTIONMRC-43-00Issued: Monday, 28 August 2000NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT RESEARCHFINDINGS RELEVANT TO CJD AND BSETerry S. Singeltary Sr.P.O. Box 42Bacliff, Texas USA 775189/13/2005http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdfTSS#################### https://lists.aegee.org/bse-l.html #################### Labels: MAD COW FEED IN COMMERCE USAposted by Terry S. Singeltary Sr. 5:57 PM4 Comments: Terry S. Singeltary Sr. said... ##################### Bovine Spongiform Encephalopathy #####################Subject: MAD COW FEED BAN WARNING LETTER ISSUED MAY 17, 2006 Date: June 27, 2006 at 7:42 am PST Public Health Service Food and Drug AdministrationNew Orleans District 297 Plus Park Blvd. Nashville, TN 37217Telephone: 615-781-5380 Fax: 615-781-5391May 17, 2006WARNING LETTER NO. 2006-NOL-06FEDERAL EXPRESS OVERNIGHT DELIVERYMr. William Shirley, Jr., Owner Louisiana.DBA Riegel By-Products 2621 State Street Dallas, Texas 75204Dear Mr. Shirley:On February 12, 17, 21, and 22, 2006, a U.S. Food & Drug Administration (FDA) investigator inspected your rendering plant, located at 509 Fortson Street, Shreveport, Louisiana. The inspection revealed significant deviations from the requirements set forth in Title 21, Code of Federal Regulations, Part 589.2000 [21 CFR 589.2000], Animal Proteins Prohibited in Ruminant Feed. This regulation is intended to prevent the establishment and amplification of Bovine Spongiform Encephalopathy (BSE). You failed to follow the requirements of this regulation; products being manufactured and distributed by your facility are misbranded within the meaning of Section 403(a)(1) [21 USC 343(a)(1)] of the Federal Food, Drug, and Cosmetic Act (the Act).Our investigation found you failed to provide measures, including sufficient written procedures, to prevent commingling or cross-contamination and to maintain sufficient written procedures [21 CFR 589.2000(e)] because:You failed to use clean-out procedures or other means adequate to prevent carryover of protein derived from mammalian tissues into animal protein or feeds which may be used for ruminants. For example, your facility uses the same equipment to process mammalian and poultry tissues. However, you use only hot water to clean the cookers between processing tissues from each species. You do not clean the auger, hammer mill, grinder, and spouts after processing mammalian tissues.You failed to maintain written procedures specifying the clean-out procedures or other means to prevent carryover of protein derived from mammalian tissues into feeds which may be used for ruminants.As a result . the poultry meal you manufacture may contain protein derived from mammalian tissues prohibited in ruminant feed. Pursuant to 21 CFR 589.2000(e)(1)(i), any products containing or may contain protein derived from mammalian tissues must be labeled, "Do not feed to cattle or other ruminants." Since you failed to label a product which may contain protein derived from mammalian tissues with the required cautionary statement. the poultry meal is misbranded under Section 403(a)(1) [21 USC 343(a)(1)] of the Act.This letter is not intended as an all-inclusive list of violations at your facility. As a manufacturer of materials intended for animal feed use, you are responsible for ensuring your overall operation and the products you manufacture and distribute are in compliance with the law. You should take prompt action to correct these violations, and you should establish a system whereby violations do not recur. Failure to promptly correct these violations may result in regulatory action, such as seizure and/or injunction, without further notice.You should notify this office in writing within 15 working days of receiving this letter, outlining the specific steps you have taken to bring your firm into compliance with the law. Your response should include an explanation of each step taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within 15 working days, state the reason for the delay and the date by which the corrections will be completed. Include copies of any available documentation demonstrating corrections have been made.Your reply should be directed to Mark W. Rivero, Compliance Officer, U.S. Food and Drug Administration, 2424 Edenborn Avenue, Suite 410, Metairie, Louisiana 70001. If you have questions regarding any issue in this letter, please contact Mr. Rivero at (504) 219-8818, extension 103.Sincerely,/SCarol S. Sanchez Acting District Director New Orleans Districthttp://www.fda.gov/foi/warning_letters/g5883d.htmAHH, with all the bad news about FDA et al on there lack of enforcement, I would have expected a token mad cow feed ban warning letter or two to pop up now. what would really be interesting would be to see all violations of the mad cow feed ban, large and small, from all states. ...tss#################### https://lists.aegee.org/bse-l.html ####################Subject: [Docket No. 03-025IFA] SRMs and Non-Ambulatory disabled cattle[TSS] Date: October 6, 2005 at 2:28 pm PST[Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirement for the Disposition of Non-Ambulatory Disabled Cattle03-025IFA 03-025IFA-2 Terry S. SingeltaryPage 1 of 17From: Terry S. Singeltary Sr. [flounder9@verizon.net]Sent: Thursday, September 08, 2005 6:17 PMTo: fsis.regulationscomments@fsis.usda.govSubject: [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirementsfor the Disposition of Non-Ambulatory Disabled CattleGreetings FSIS,I would kindly like to submit the following to [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food andRequirements for the Disposition of Non-Ambulatory Disabled CattleTHE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled CattleBroken bones and such may be the first signs of a sub clinical BSE/TSE Non-Ambulatory Disabled Cattle ;SUB CLINICAL PRION INFECTIONMRC-43-00Issued: Monday, 28 August 2000NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT RESEARCHFINDINGS RELEVANT TO CJD AND BSETerry S. Singeltary Sr.P.O. Box 42Bacliff, Texas USA 775189/13/2005http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdfTSS6:48 PM Terry S. Singeltary Sr. said... ##################### Bovine Spongiform Encephalopathy #####################CJD WATCH MESSAGE BOARD TSS Monthly Creutzfeldt Jakob disease statistics July 3, 2006 Mon Jul 3, 2006 11:47 68.238.110.55Date: July 03, 2006 Time: 15:15 Monthly Creutzfeldt Jakob disease statistics publishedThe Department of Health is today issuing the latest information about the numbers of known cases of Creutzfeldt Jakob disease. This includes cases of variant Creutzfeldt Jakob disease (vCJD) - the form of the disease thought to be linked to BSE. The position is as follows:Definite and probable CJD cases in the UK:As at 30 June 2006Summary of vCJD casesDeathsDeaths from definite vCJD (confirmed): 111Deaths from probable vCJD (without neuropathological confirmation): 44Deaths from probable vCJD (neuropathological confirmation pending): 1Number of deaths from definite or probable vCJD (as above): 156AliveNumber of probable vCJD cases still alive: 5Total number of definite or probable vCJD (dead and alive): 161The next table will be published on Monday 7th August 2006Referrals: a simple count of all the cases which have been referred to the National CJD Surveillance Unit for further investigation in the year in question. CJD may be no more than suspected; about half the cases referred in the past have turned out not to be CJD. Cases are notified to the Unit from a variety of sources including neurologists, neuropathologists, neurophysiologists, general physicians, psychiatrists, electroencephalogram (EEG) departments etc. As a safety net, death certificates coded under the specific rubrics 046.1 and 331.9 in the 9th ICD Revisions are obtained from the Office for National Statistics in England and Wales, the General Register Office for Scotland and the General Register Office for Northern Ireland.Deaths: All columns show the number of deaths that have occurred in definite and probable cases of all types of CJD and GSS in the year shown. The figures include both cases referred to the Unit for investigation while the patient was still alive and those where CJD was only discovered post mortem (including a few cases picked up by the Unit from death certificates). There is therefore no read across from these columns to the referrals column. The figures will be subject to retrospective adjustment as diagnoses are confirmed.Definite cases: this refers to the diagnostic status of cases. In definite cases the diagnosis will have been pathologically confirmed, in most cases by post mortem examination of brain tissue (rarely it may be possible to establish a definite diagnosis by brain biopsy while the patient is still alive).Probable vCJD cases: are those who fulfil the 'probable' criteria set out in the Annex and are either still alive, or have died and await post mortem pathological confirmation. Those still alive will always be shown within the current year's figures.Sporadic: Classic CJD cases with typical EEG and brain pathology. Sporadic cases appear to occur spontaneously with no identifiable cause and account for 85% of all cases.Probable sporadic: Cases with a history of rapidly progressive dementia, typical EEG and at least two of the following clinical features; myoclonus, visual or cerebellar signs, pyramidal/extrapyramidalsigns or akinetic mutism.Iatrogenic: where infection with classic CJD has occurred accidentally as the result of a medical procedure. All UK cases have resulted from treatment with human derived pituitary growth hormones or from grafts using dura mater (a membrane lining the skull).Familial: cases occurring in families associated with mutations in the PrP gene (10 - 15% of cases).GSS: Gerstmann-Straussler-Scheinker syndrome - an exceedingly rare inherited autosomal dominant disease, typified by chronic progressive ataxia and terminal dementia. The clinical duration is from 2 to 10 years, much longer than for CJD.vCJD: Variant CJD, the hitherto unrecognised variant of CJD discovered by the National CJD Surveillance Unit and reported in The Lancet on 6 April 1996. This is characterised clinically by a progressive neuropsychiatric disorder leading to ataxia, dementia and myoclonus (or chorea) without the typical EEG appearance of CJD. Neuropathology shows marked spongiform change and extensive florid plaques throughout the brain.Definite vCJD cases still alive: These will be cases where the diagnosis has been pathologically confirmed (by brain biopsy).Related linksDownload cjd annual stats (PDF, 145K)Notes to editorANNEXDIAGNOSTIC CRITERIA FOR VARIANT CJDI A) PROGRESSIVE NEUROPSYCHIATRIC DISORDERB) DURATION OF ILLNESS > 6 MONTHSC) ROUTINE INVESTIGATIONS DO NOT SUGGEST AN ALTERNATIVE DIAGNOSISD) NO HISTORY OF POTENTIAL IATROGENIC EXPOSUREII A) EARLY PSYCHIATRIC SYMPTOMS *B) PERSISTENT PAINFUL SENSORY SYMPTOMS **C) ATAXIAD) MYOCLONUS OR CHOREA OR DYSTONIAE) DEMENTIAIII A) EEG DOES NOT SHOW THE TYPICAL APPEARANCE OF SPORADICCJD *** (OR NO EEG PERFORMED)B) BILATERAL PULVINAR HIGH SIGNAL ON MRI SCANIV A) POSITIVE TONSIL BIOPSYDEFINITE: IA (PROGRESSIVE NEUROPSYCHIATRIC DISORDER) and NEUROPATHOLOGICAL CONFIRMATION OF vCJD ****PROBABLE: I and 4/5 OF II and III A and III Bor I and IV A* depression, anxiety, apathy, withdrawal, delusions.** this includes both frank pain and/ or unpleasant dysaesthesia*** generalised triphasic periodic complexes at approximately one per second****spongiform change and extensive PrP deposition with florid plaques, throughout the cerebrum and cerebellum.http://www.wired-gov.net/WGLaunch.aspx?ARTCL=39920TOTAL CASES OF SPORADIC CJD (DEATHS)http://www.eurocjd.ed.ac.uk/sporadic.htmTOTAL CASES OF FAMILIAL/GENETIC CJD AND IATROGENIC CJD DEATHS TO 31 MARCH 2006http://www.eurocjd.ed.ac.uk/genetic.htmCJD USA(please note steady increase in sporadic cjd from 1997 to 2004 with steady increase in type 'UNKNOWN' CJD? also, seems like they could come up with a better, more readable chart. ...TSS)http://www.cjdsurveillance.com/resources-casereport.htmlHUMAN and ANIMAL TSE Classifications i.e. mad cow disease and the UKBSEnvCJD only theoryTSEs have been rampant in the USA for decades in many species, and they all have been rendered and fed back to animals for human/animal consumption. I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2005. With all the science to date refuting it, to continue to validate this myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, surgical, blood, medical, cosmetics etc. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Tranmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route. This would further have to be broken down to strain of species and then the route of transmission would further have to be broken down. Accumulation and Transmission are key to the threshold from subclinical to clinical disease, and key to all this, is to stop the amplification and transmission of this agent, the spreading of, no matter what strain. BUT, to continue with this myth that the U.K. strain of BSE one strain in cows, and the nv/v CJD, one strain in humans, and that all the rest of human TSE is one single strain i.e. sporadic CJD (when to date there are 6 different phenotypes of sCJD), and that no other animal TSE transmits to humans, to continue with this masquerade will only continue to spread, expose, and kill, who knows how many more in the years and decades to come. ONE was enough for me, My Mom, hvCJD, DOD 12/14/97 confirmed, which is nothing more than another mans name added to CJD, like CJD itself, Jakob and Creutzfeldt, or Gerstmann-Straussler-Scheinker syndrome, just another CJD or human TSE, named after another human. WE are only kidding ourselves with the current diagnostic criteria for human and animal TSE, especially differentiating between the nvCJD vs the sporadic CJD strains and then the GSS strains and also the FFI fatal familial insomnia strains or the ones that mimics one or the other of those TSE? Tissue infectivity and strain typing of the many variants of the human and animal TSEs are paramount in all variants of all TSE. There must be a proper classification that will differentiate between all these human TSE in order to do this. With the CDI and other more sensitive testing coming about, I only hope that my proposal will some day be taken seriously. ...TSSCoexistence of multiple PrPSc types in individuals withCreutzfeldt-Jakob diseaseMagdalini Polymenidou, Katharina Stoeck, Markus Glatzel, Martin Vey, Anne Bellon, and Adriano AguzziSummaryBackground The molecular typing of sporadic Creutzfeldt-Jakob disease (CJD) is based on the size and glycoform ratio of protease-resistant prion protein (PrPSc), and on PRNP haplotype. On digestion with proteinase K, type 1 and type 2 PrPSc display unglycosylated core fragments of 21 kDa and 19 kDa, resulting from cleavage around amino acids 82 and 97, respectively.Methods We generated anti-PrP monoclonal antibodies to epitopes immediately preceding the differential proteinase K cleavage sites. These antibodies, which were designated POM2 and POM12, recognise type 1, but not type 2, PrPSc.Findings We studied 114 brain samples from 70 patients with sporadic CJD and three patients with variant CJD.Every patient classified as CJD type 2, and all variant CJD patients, showed POM2/POM12 reactivity in the cerebellum and other PrPSc-rich brain areas, with a typical PrPSc type 1 migration pattern.Interpretation The regular coexistence of multiple PrPSc types in patients with CJD casts doubts on the validity of electrophoretic PrPSc mobilities as surrogates for prion strains, and questions the rational basis of current CJDclassifications. ...http://neurology.thelancet.comJ Neuropsychiatry Clin Neurosci 17:489-495, November 2005 doi: 10.1176/appi.neuropsych.17.4.489 © 2005 American Psychiatric Publishing, Inc.Psychiatric Manifestations of Creutzfeldt-Jakob Disease: A 25-Year Analysis Christopher A. Wall, M.D., Teresa A. Rummans, M.D., Allen J. Aksamit, M.D., Lois E. Krahn, M.D. and V. Shane Pankratz, Ph.D. Received April 20, 2004; revised September 9, 2004; accepted September 13, 2004. From the Mayo Clinic, Department of Psychiatry and Psychology, Rochester, Minnesota; Mayo Clinic, Department of Neurology, Rochester, Minnesota. Address correspondence to Dr. Wall, Mayo Clinic, Department of Psychiatry and Psychology, Mayo Building-W11A, 200 First St., SW, Rochester, MN 55905; wall.chris@mayo.edu (E-mail).This study characterizes the type and timing of psychiatric manifestations in sporadic Creutzfeldt-Jakob disease (sCJD). Historically, sCJD has been characterized by prominent neurological symptoms, while the variant form (vCJD) is described as primarily psychiatric in presentation and course: A retrospective review of 126 sCJD patients evaluated at the Mayo Clinic from 1976-2001 was conducted. Cases were reviewed for symptoms of depression, anxiety, psychosis, behavior dyscontrol, sleep disturbances, and neurological signs during the disease course. Eighty percent of the cases demonstrated psychiatric symptoms within the first 100 days of illness, with 26% occurring at presentation. The most commonly reported symptoms in this population included sleep disturbances, psychotic symptoms, and depression. Psychiatric manifestations are an early and prominent feature of sporadic CJD, often occurring prior to formal diagnosis.snip...CONCLUSIONSHistorically, psychiatric manifestations have been described as a relatively infrequent occurrence in the sporadic form of creutzfeldt-Jakob disease. However, our findings suggest otherwise. In this study, a vast majority of the cases were noted to have at least one psychiatric symptom during the course of illness, with nearly one-quarter occurring in the prodromal or presenting phase of the illness. After comparing the frequency of neuropsychiatric symptoms in sporadic CJD to studies describing the variant form of CJD, we found that there are fewer clinical differences than previously reported.5-7 While the age of patients with vCJD presentation is significantly younger and the course of illness is longer, the type and timing of psychiatric manifestations appear similar between these two diseases. ...snip...http://neuro.psychiatryonline.org/cgi/content/abstract/17/4/489Personal Communication-------- Original Message --------Subject: re-BSE prions propagate aseither variant CJD-like or sporadic CJD Date: Thu, 28 Nov 2002 10:23:43-0000 From: "Asante, Emmanuel A" To: "'flounder@wt.net'"Dear Terry,I have been asked by Professor Collinge to respond to your request. I ama Senior Scientist in the MRC Prion Unit and the lead author on thepaper. I have attached a pdf copy of the paper for your attention. Thankyou for your interest in the paper.In respect of your first question, the simple answer is, yes. As youwill find in the paper, we have managed to associate the alternatephenotype to type 2 PrPSc, the commonest sporadic CJD.It is too early to be able to claim any further sub-classification inrespect of Heidenhain variant CJD or Vicky Rimmer's version. It willtake further studies, which are on-going, to establish if there aresub-types to our initial finding which we are now reporting. The mainpoint of the paper is that, as well as leading to the expected newvariant CJD phenotype, BSE transmission to the 129-methionine genotypecan lead to an alternate phenotype which is indistinguishable from type2 PrPSc.I hope reading the paper will enlighten you more on the subject. If Ican be of any further assistance please to not hesitate to ask. Best wishes.Emmanuel Asante<> ____________________________________Dr. Emmanuel A Asante MRC Prion Unit & Neurogenetics Dept. ImperialCollege School of Medicine (St. Mary's) Norfolk Place, LONDON W2 1PGTel: +44 (0)20 7594 3794 Fax: +44 (0)20 7706 3272 email:e.asante@ic.ac.uk (until 9/12/02)New e-mail: e.asante@prion.ucl.ac.uk (active from now)____________________________________Full Text Diagnosis and Reporting of Creutzfeldt-Jakob Disease Singeltary, Sr et al. JAMA.2001; 285: 733-734http://jama.ama-assn.org/cgi/content/full/285/6/733?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=dignosing+and+reporting+creutzfeldt+jakob+disease&searchid=1048865596978_1528&stored_search=&FIRSTINDEX=0&journalcode=jamaTSS#################### https://lists.aegee.org/bse-l.html ####################6:53 PM Terry S. Singeltary Sr. said... Latest Information (as of July 4, 2006 - 17:30 EST) Final test results have confirmed bovine spongiform encephalopathy (BSE) in a mature cross-bred beef cow from Manitoba. The Canadian Food Inspection Agency (CFIA) is conducting a comprehensive investigation. Officials have confirmed the animal was purchased by the owner as part of an assembled group of cattle in 1992. This means that the animal was at least 15 years of age and would have been born well before the 1997 introduction of Canada’s feed ban. As a priority, investigators are attempting to locate the birth farm, which will provide the basis needed to identify the animal’s herdmates and feed to which it may have been exposed at a young age. Given the animal’s age, investigative efforts may be constrained by few surviving animals and limited sources of information, such as detailed records. A calf born to the affected animal in 2004 is also being traced.---------------------------------------------------------------------------- ----http://www.inspection.gc.ca/english/anima/heasan/disemala/bseesb/situatione.shtmlTSS6:55 PM Terry S. Singeltary Sr. said... ##################### Bovine Spongiform Encephalopathy #####################Subject: MAD COW FEED RECALLS ENFORCEMENT REPORT FOR AUGUST 9, 2006 KY, LA, MS, AL, GA, AND TN 11,000+ TONS Date: August 16, 2006 at 9:19 am PSTRECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINE - CLASS II ______________________________ PRODUCT Bulk custom made dairy feed, Recall # V-115-6 CODE None RECALLING FIRM/MANUFACTURER Hiseville Feed & Seed Co., Hiseville, KY, by telephone and letter on or about July 14, 2006. FDA initiated recall is ongoing. REASON Custom made feeds contain ingredient called Pro-Lak which may contain ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE Approximately 2,223 tons DISTRIBUTION KY______________________________ PRODUCT Bulk custom made dairy feed, Recall # V-116-6 CODE None RECALLING FIRM/MANUFACTURER Rips Farm Center, Tollesboro, KY, by telephone and letter on July 14, 2006. FDA initiated recall is ongoing. REASON Custom made feeds contain ingredient called Pro-Lak which may contain ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 1,220 tons DISTRIBUTION KY______________________________ PRODUCT Bulk custom made dairy feed, Recall # V-117-6 CODE None RECALLING FIRM/MANUFACTURER Kentwood Co-op, Kentwood, LA, by telephone on June 27, 2006. FDA initiated recall is completed. REASON Possible contamination of animal feed ingredients, including ingredients that are used in feed for dairy animals, with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 40 tons DISTRIBUTION LA and MS______________________________ PRODUCT Bulk Dairy Feed, Recall V-118-6 CODE None RECALLING FIRM/MANUFACTURER Cal Maine Foods, Inc., Edwards, MS, by telephone on June 26, 2006. FDA initiated recall is complete. REASON Possible contamination of animal feed ingredients, including ingredients that are used in feed for dairy animals, with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 7,150 tons DISTRIBUTION MS______________________________ PRODUCT Bulk custom dairy pre-mixes, Recall # V-119-6 CODE None RECALLING FIRM/MANUFACTURER Walthall County Co-op, Tylertown, MS, by telephone on June 26, 2006. Firm initiated recall is complete. REASON Possible contamination of dairy animal feeds with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 87 tons DISTRIBUTION MS______________________________ PRODUCT Bulk custom dairy pre-mixes, Recall # V-120-6 CODE None RECALLING FIRM/MANUFACTURER Ware Milling Inc., Houston, MS, by telephone on June 23, 2006. Firm initiated recall is complete. REASON Possible contamination of dairy animal feeds with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE 350 tons DISTRIBUTION AL and MS______________________________ PRODUCT a) Tucker Milling, LLC Tm 32% Sinking Fish Grower, #2680-Pellet, 50 lb. bags, Recall # V-121-6; b) Tucker Milling, LLC #31120, Game Bird Breeder Pellet, 50 lb. bags, Recall # V-122-6; c) Tucker Milling, LLC #31232 Game Bird Grower, 50 lb. bags, Recall # V-123-6; d) Tucker Milling, LLC 31227-Crumble, Game Bird Starter, BMD Medicated, 50 lb bags, Recall # V-124-6; e) Tucker Milling, LLC #31120, Game Bird Breeder, 50 lb bags, Recall # V-125-6; f) Tucker Milling, LLC #30230, 30 % Turkey Starter, 50 lb bags, Recall # V-126-6; g) Tucker Milling, LLC #30116, TM Broiler Finisher, 50 lb bags, Recall # V-127-6 CODE All products manufactured from 02/01/2005 until 06/20/2006 RECALLING FIRM/MANUFACTURER Recalling Firm: Tucker Milling LLC, Guntersville, AL, by telephone and visit on June 20, 2006, and by letter on June 23, 2006. Manufacturer: H. J. Baker and Brothers Inc., Stamford, CT. Firm initiated recall is ongoing. REASON Poultry and fish feeds which were possibly contaminated with ruminant based protein were not labeled as "Do not feed to ruminants". VOLUME OF PRODUCT IN COMMERCE 7,541-50 lb bags DISTRIBUTION AL, GA, MS, and TNEND OF ENFORCEMENT REPORT FOR AUGUST 9, 2006###http://www.fda.gov/bbs/topics/ENFORCE/2006/ENF00964.htmlGOTTA LOVE THOSE FDA/USDA TRIPLE BSE FIREWALLS. ...TSSWE know now, and we knew decades ago, that 5.5 grams of suspect feed in TEXAS was enough to kill 100 cows ;http://www.fda.gov/bbs/topics/NEWS/2001/NEW00752.htmlNOT TO FORGET THE TEXAS MAD COW THAT DID GET AWAY ;http://www.fda.gov/bbs/topics/news/2004/NEW01061.htmllook at the table and you'll see that as little as 1 mg (or 0.001 gm) caused 7% (1 of 14) of the cows to come down with BSE;Risk of oral infection with bovine spongiform encephalopathy agent in primatesCorinne Ida Lasmézas, Emmanuel Comoy, Stephen Hawkins, Christian Herzog, Franck Mouthon, Timm Konold, Frédéric Auvré, Evelyne Correia, Nathalie Lescoutra-Etchegaray, Nicole Salès, Gerald Wells, Paul Brown, Jean-Philippe Deslys Summary The uncertain extent of human exposure to bovine spongiform encephalopathy (BSE)--which can lead to variant Creutzfeldt-Jakob disease (vCJD)--is compounded by incomplete knowledge about the efficiency of oral infection and the magnitude of any bovine-to-human biological barrier to transmission. We therefore investigated oral transmission of BSE to non-human primates. We gave two macaques a 5 g oral dose of brain homogenate from a BSE-infected cow. One macaque developed vCJD-like neurological disease 60 months after exposure, whereas the other remained free of disease at 76 months. On the basis of these findings and data from other studies, we made a preliminary estimate of the food exposure risk for man, which provides additional assurance that existing public health measures can prevent transmission of BSE to man.snip...BSE bovine brain inoculum100 g 10 g 5 g 1 g 100 mg 10 mg 1 mg 0·1 mg 0·01 mgPrimate (oral route)* 1/2 (50%)Cattle (oral route)* 10/10 (100%) 7/9 (78%) 7/10 (70%) 3/15 (20%) 1/15 (7%) 1/15 (7%)RIII mice (ic ip route)* 17/18 (94%) 15/17 (88%) 1/14 (7%)PrPres biochemical detectionThe comparison is made on the basis of calibration of the bovine inoculum used in our study with primates against a bovine brain inoculum with a similar PrPres concentration that wasinoculated into mice and cattle.8 *Data are number of animals positive/number of animals surviving at the time of clinical onset of disease in the first positive animal (%). The accuracy ofbioassays is generally judged to be about plus or minus 1 log. ic ip=intracerebral and intraperitoneal.Table 1: Comparison of transmission rates in primates and cattle infected orally with similar BSE brain inoculaPublished online January 27, 2005http://www.thelancet.com/journal/journal.isaIt is clear that the designing scientists mustalso have shared Mr Bradley’s surprise at the results because all the doselevels right down to 1 gram triggered infection.http://www.bseinquiry.gov.uk/files/ws/s145d.pdf26. It also appears to me that Mr Bradley’s answer (that it would take less than say 100grams) was probably given with the benefit of hindsight; particularly if oneconsiders that later in the same answer Mr Bradley expresses his surprise that itcould take as little of 1 gram of brain to cause BSE by the oral route within thesame species. This information did not become available until the "attack rate"experiment had been completed in 1995/96. This was a titration experimentdesigned to ascertain the infective dose. A range of dosages was used to ensurethat the actual result was within both a lower and an upper limit within the studyand the designing scientists would not have expected all the dose levels to triggerinfection. The dose ranges chosen by the most informed scientists at that timeranged from 1 gram to three times one hundred grams. It is clear that the designingscientists must have also shared Mr Bradley’s surprise at the results because all thedose levels right down to 1 gram triggered infection.http://www.bseinquiry.gov.uk/files/ws/s147f.pdfRe: BSE .1 GRAM LETHAL NEW STUDY SAYS via W.H.O. Dr Maura Ricketts[BBC radio 4 FARM news]http://www.maddeer.org/audio/BBC4farmingtoday2_1_03.ramhttp://www.fda.gov/ohrms/dockets/ac/03/slides/3923s1_OPH.htm2) Infectious dose:To cattle: 1 gram of infected brain material (by oral ingestion)http://www.inspection.gc.ca/english/sci/bio/bseesbe.shtmlTerry S. Singeltary Sr.P.O. Box 42Bacliff, Texas USA 77518[Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirement for the Disposition of Non-Ambulatory Disabled Cattle03-025IFA 03-025IFA-2 Terry S. SingeltaryPage 1 of 17From: Terry S. Singeltary Sr. [flounder9@verizon.net]Sent: Thursday, September 08, 2005 6:17 PMTo: fsis.regulationscomments@fsis.usda.govSubject: [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirementsfor the Disposition of Non-Ambulatory Disabled CattleGreetings FSIS,I would kindly like to submit the following to [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food andRequirements for the Disposition of Non-Ambulatory Disabled CattleTHE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled CattleBroken bones and such may be the first signs of a sub clinical BSE/TSE Non-Ambulatory Disabled Cattle ;SUB CLINICAL PRION INFECTIONMRC-43-00Issued: Monday, 28 August 2000NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT RESEARCHFINDINGS RELEVANT TO CJD AND BSETerry S. Singeltary Sr.P.O. Box 42Bacliff, Texas USA 775189/13/2005http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdfTSS#################### https://lists.aegee.org/bse-l.html ####################Labels: MAD COW FEED IN COMMERCE USA
posted by Terry S. Singeltary Sr. | 5:57 PM
##################### Bovine Spongiform Encephalopathy #####################Subject: MAD COW FEED BAN WARNING LETTER ISSUED MAY 17, 2006Date: June 27, 2006 at 7:42 am PST Public Health Service Food and Drug AdministrationNew Orleans District297 Plus Park Blvd.Nashville, TN 37217 Telephone: 615-781-5380Fax: 615-781-5391May 17, 2006 WARNING LETTER NO. 2006-NOL-06 FEDERAL EXPRESSOVERNIGHT DELIVERY Mr. William Shirley, Jr., OwnerLouisiana.DBA Riegel By-Products2621 State StreetDallas, Texas 75204 Dear Mr. Shirley: On February 12, 17, 21, and 22, 2006, a U.S. Food & Drug Administration (FDA) investigator inspected your rendering plant, located at 509 Fortson Street, Shreveport, Louisiana. The inspection revealed significant deviations from the requirements set forth in Title 21, Code of Federal Regulations, Part 589.2000 [21 CFR 589.2000], Animal Proteins Prohibited in Ruminant Feed. This regulation is intended to prevent the establishment and amplification of Bovine Spongiform Encephalopathy (BSE). You failed to follow the requirements of this regulation; products being manufactured and distributed by your facility are misbranded within the meaning of Section 403(a)(1) [21 USC 343(a)(1)] of the Federal Food, Drug, and Cosmetic Act (the Act). Our investigation found you failed to provide measures, including sufficient written procedures, to prevent commingling or cross-contamination and to maintain sufficient written procedures [21 CFR 589.2000(e)] because: You failed to use clean-out procedures or other means adequate to prevent carryover of protein derived from mammalian tissues into animal protein or feeds which may be used for ruminants. For example, your facility uses the same equipment to process mammalian and poultry tissues. However, you use only hot water to clean the cookers between processing tissues from each species. You do not clean the auger, hammer mill, grinder, and spouts after processing mammalian tissues. You failed to maintain written procedures specifying the clean-out procedures or other means to prevent carryover of protein derived from mammalian tissues into feeds which may be used for ruminants. As a result . the poultry meal you manufacture may contain protein derived from mammalian tissues prohibited in ruminant feed. Pursuant to 21 CFR 589.2000(e)(1)(i), any products containing or may contain protein derived from mammalian tissues must be labeled, "Do not feed to cattle or other ruminants." Since you failed to label a product which may contain protein derived from mammalian tissues with the required cautionary statement. the poultry meal is misbranded under Section 403(a)(1) [21 USC 343(a)(1)] of the Act. This letter is not intended as an all-inclusive list of violations at your facility. As a manufacturer of materials intended for animal feed use, you are responsible for ensuring your overall operation and the products you manufacture and distribute are in compliance with the law. You should take prompt action to correct these violations, and you should establish a system whereby violations do not recur. Failure to promptly correct these violations may result in regulatory action, such as seizure and/or injunction, without further notice. You should notify this office in writing within 15 working days of receiving this letter, outlining the specific steps you have taken to bring your firm into compliance with the law. Your response should include an explanation of each step taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within 15 working days, state the reason for the delay and the date by which the corrections will be completed. Include copies of any available documentation demonstrating corrections have been made. Your reply should be directed to Mark W. Rivero, Compliance Officer, U.S. Food and Drug Administration, 2424 Edenborn Avenue, Suite 410, Metairie, Louisiana 70001. If you have questions regarding any issue in this letter, please contact Mr. Rivero at (504) 219-8818, extension 103. Sincerely, /S Carol S. SanchezActing District DirectorNew Orleans District http://www.fda.gov/foi/warning_letters/g5883d.htm AHH, with all the bad news about FDA et al on there lack of enforcement, I would have expected a token mad cow feed ban warning letter or two to pop up now. what would really be interesting would be to see all violations of the mad cow feed ban, large and small, from all states. ...tss#################### https://lists.aegee.org/bse-l.html ####################Subject: [Docket No. 03-025IFA] SRMs and Non-Ambulatory disabled cattle[TSS]Date: October 6, 2005 at 2:28 pm PST[Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirement for the Disposition of Non-Ambulatory Disabled Cattle03-025IFA03-025IFA-2Terry S. SingeltaryPage 1 of 17From: Terry S. Singeltary Sr. [flounder9@verizon.net]Sent: Thursday, September 08, 2005 6:17 PMTo: fsis.regulationscomments@fsis.usda.govSubject: [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirementsfor the Disposition of Non-Ambulatory Disabled CattleGreetings FSIS,I would kindly like to submit the following to [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food andRequirements for the Disposition of Non-Ambulatory Disabled CattleTHE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled CattleBroken bones and such may be the first signs of a sub clinical BSE/TSE Non-Ambulatory Disabled Cattle ;SUB CLINICAL PRION INFECTIONMRC-43-00Issued: Monday, 28 August 2000NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT RESEARCHFINDINGS RELEVANT TO CJD AND BSETerry S. Singeltary Sr.P.O. Box 42Bacliff, Texas USA 775189/13/2005http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdf TSS
##################### Bovine Spongiform Encephalopathy #####################CJD WATCH MESSAGE BOARD TSSMonthly Creutzfeldt Jakob disease statistics July 3, 2006Mon Jul 3, 2006 11:4768.238.110.55Date: July 03, 2006 Time: 15:15 Monthly Creutzfeldt Jakob disease statistics published The Department of Health is today issuing the latest information about the numbers of known cases of Creutzfeldt Jakob disease. This includes cases of variant Creutzfeldt Jakob disease (vCJD) - the form of the disease thought to be linked to BSE. The position is as follows:Definite and probable CJD cases in the UK:As at 30 June 2006Summary of vCJD casesDeathsDeaths from definite vCJD (confirmed): 111Deaths from probable vCJD (without neuropathological confirmation): 44Deaths from probable vCJD (neuropathological confirmation pending): 1Number of deaths from definite or probable vCJD (as above): 156AliveNumber of probable vCJD cases still alive: 5Total number of definite or probable vCJD (dead and alive): 161The next table will be published on Monday 7th August 2006Referrals: a simple count of all the cases which have been referred to the National CJD Surveillance Unit for further investigation in the year in question. CJD may be no more than suspected; about half the cases referred in the past have turned out not to be CJD. Cases are notified to the Unit from a variety of sources including neurologists, neuropathologists, neurophysiologists, general physicians, psychiatrists, electroencephalogram (EEG) departments etc. As a safety net, death certificates coded under the specific rubrics 046.1 and 331.9 in the 9th ICD Revisions are obtained from the Office for National Statistics in England and Wales, the General Register Office for Scotland and the General Register Office for Northern Ireland.Deaths: All columns show the number of deaths that have occurred in definite and probable cases of all types of CJD and GSS in the year shown. The figures include both cases referred to the Unit for investigation while the patient was still alive and those where CJD was only discovered post mortem (including a few cases picked up by the Unit from death certificates). There is therefore no read across from these columns to the referrals column. The figures will be subject to retrospective adjustment as diagnoses are confirmed.Definite cases: this refers to the diagnostic status of cases. In definite cases the diagnosis will have been pathologically confirmed, in most cases by post mortem examination of brain tissue (rarely it may be possible to establish a definite diagnosis by brain biopsy while the patient is still alive).Probable vCJD cases: are those who fulfil the 'probable' criteria set out in the Annex and are either still alive, or have died and await post mortem pathological confirmation. Those still alive will always be shown within the current year's figures.Sporadic: Classic CJD cases with typical EEG and brain pathology. Sporadic cases appear to occur spontaneously with no identifiable cause and account for 85% of all cases.Probable sporadic: Cases with a history of rapidly progressive dementia, typical EEG and at least two of the following clinical features; myoclonus, visual or cerebellar signs,pyramidal/extrapyramidalsigns or akinetic mutism.Iatrogenic: where infection with classic CJD has occurred accidentally as the result of a medical procedure. All UK cases have resulted from treatment with human derived pituitary growth hormones or from grafts using dura mater (a membrane lining the skull).Familial: cases occurring in families associated with mutations in the PrP gene (10 - 15% of cases).GSS: Gerstmann-Straussler-Scheinker syndrome - an exceedingly rare inherited autosomal dominant disease, typified by chronic progressive ataxia and terminal dementia. The clinical duration is from 2 to 10 years, much longer than for CJD.vCJD: Variant CJD, the hitherto unrecognised variant of CJD discovered by the National CJD Surveillance Unit and reported in The Lancet on 6 April 1996. This is characterised clinically by a progressive neuropsychiatric disorder leading to ataxia, dementia and myoclonus (or chorea) without the typical EEG appearance of CJD. Neuropathology shows marked spongiform change and extensive florid plaques throughout the brain.Definite vCJD cases still alive: These will be cases where the diagnosis has been pathologically confirmed (by brain biopsy).Related linksDownload cjd annual stats (PDF, 145K)Notes to editorANNEXDIAGNOSTIC CRITERIA FOR VARIANT CJDI A) PROGRESSIVE NEUROPSYCHIATRIC DISORDERB) DURATION OF ILLNESS > 6 MONTHSC) ROUTINE INVESTIGATIONS DO NOT SUGGEST AN ALTERNATIVE DIAGNOSISD) NO HISTORY OF POTENTIAL IATROGENIC EXPOSUREII A) EARLY PSYCHIATRIC SYMPTOMS *B) PERSISTENT PAINFUL SENSORY SYMPTOMS **C) ATAXIAD) MYOCLONUS OR CHOREA OR DYSTONIAE) DEMENTIAIII A) EEG DOES NOT SHOW THE TYPICAL APPEARANCE OF SPORADICCJD *** (OR NO EEG PERFORMED)B) BILATERAL PULVINAR HIGH SIGNAL ON MRI SCANIV A) POSITIVE TONSIL BIOPSYDEFINITE: IA (PROGRESSIVE NEUROPSYCHIATRIC DISORDER) and NEUROPATHOLOGICAL CONFIRMATION OF vCJD ****PROBABLE: I and 4/5 OF II and III A and III Bor I and IV A* depression, anxiety, apathy, withdrawal, delusions.** this includes both frank pain and/ or unpleasant dysaesthesia*** generalised triphasic periodic complexes at approximately one per second****spongiform change and extensive PrP deposition with florid plaques, throughout the cerebrum and cerebellum.http://www.wired-gov.net/WGLaunch.aspx?ARTCL=39920TOTAL CASES OF SPORADIC CJD (DEATHS)http://www.eurocjd.ed.ac.uk/sporadic.htmTOTAL CASES OF FAMILIAL/GENETIC CJD AND IATROGENIC CJDDEATHS TO 31 MARCH 2006 http://www.eurocjd.ed.ac.uk/genetic.htmCJD USA(please note steady increase in sporadic cjd from 1997 to 2004 with steady increase in type 'UNKNOWN' CJD? also, seems like they could come up with a better, more readable chart. ...TSS)http://www.cjdsurveillance.com/resources-casereport.htmlHUMAN and ANIMAL TSE Classifications i.e. mad cowdisease and the UKBSEnvCJD only theoryTSEs have been rampant in the USA for decades in manyspecies, and they all have been rendered and fed backto animals for human/animal consumption. I propose thatthe current diagnostic criteria for human TSEs onlyenhances and helps the spreading of human TSE from thecontinued belief of the UKBSEnvCJD only theory in 2005.With all the science to date refuting it, to continueto validate this myth, will only spread this TSE agentthrough a multitude of potential routes and sourcesi.e. consumption, surgical, blood, medical, cosmeticsetc. I propose as with Aguzzi, Asante, Collinge,Caughey, Deslys, Dormont, Gibbs, Ironside, Manuelidis,Marsh, et al and many more, that the world of TSETranmissible Spongiform Encephalopathy is far from anexact science, but there is enough proven science todate that this myth should be put to rest once and forall, and that we move forward with a new classificationfor human and animal TSE that would properly identifythe infected species, the source species, and then theroute. This would further have to be broken down tostrain of species and then the route of transmissionwould further have to be broken down. Accumulation andTransmission are key to the threshold from subclinicalto clinical disease, and key to allthis, is to stop the amplification and transmission ofthis agent, the spreading of, no matter what strain.BUT, to continue with this myth that the U.K. strain ofBSE one strain in cows, and the nv/v CJD, one strain inhumans, and that all the rest of human TSE is onesingle strain i.e. sporadic CJD (when to date there are6 different phenotypes of sCJD), and that no otheranimal TSE transmits to humans, to continue with thismasquerade will only continue to spread, expose, andkill, who knows how many more in the years and decadesto come. ONE was enough for me, My Mom, hvCJD, DOD12/14/97 confirmed, which is nothing more than anothermans name added to CJD, like CJD itself, Jakob andCreutzfeldt, or Gerstmann-Straussler-Scheinkersyndrome, just another CJD or human TSE, named afteranother human. WE are only kidding ourselves with thecurrent diagnostic criteria for human and animal TSE,especially differentiating between the nvCJD vs thesporadic CJD strains and then the GSS strains and alsothe FFI fatal familial insomnia strains or the onesthat mimics one or the other of those TSE? Tissueinfectivity and strain typing of the many variants ofthe human and animal TSEs are paramount in all variantsof all TSE. There must be a proper classification thatwill differentiate between all these human TSE in orderto do this. With the CDI and other more sensitivetesting coming about, I only hope that my proposal willsome day be taken seriously. ...TSSCoexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease Magdalini Polymenidou, Katharina Stoeck, MarkusGlatzel, Martin Vey, Anne Bellon, and Adriano Aguzzi Summary Background The molecular typing of sporadicCreutzfeldt-Jakob disease (CJD) is based on the sizeand glycoform ratio of protease-resistant prion protein (PrPSc), andon PRNP haplotype. On digestion with proteinase K, type1 and type 2 PrPSc display unglycosylated core fragments of21 kDa and 19 kDa, resulting from cleavage around amino acids 82 and 97, respectively. Methods We generated anti-PrP monoclonal antibodies toepitopes immediately preceding the differential proteinase K cleavage sites. These antibodies, which weredesignated POM2 and POM12, recognise type 1, but nottype 2, PrPSc. Findings We studied 114 brain samples from 70 patientswith sporadic CJD and three patients with variant CJD. Every patient classified as CJD type 2, and all variantCJD patients, showed POM2/POM12 reactivity in the cerebellum and other PrPSc-rich brain areas, with atypical PrPSc type 1 migration pattern. Interpretation The regular coexistence of multiplePrPSc types in patients with CJD casts doubts on thevalidity of electrophoretic PrPSc mobilities as surrogates forprion strains, and questions the rational basis ofcurrent CJD classifications. ...http://neurology.thelancet.com J Neuropsychiatry Clin Neurosci 17:489-495, November 2005doi: 10.1176/appi.neuropsych.17.4.489© 2005 American Psychiatric Publishing, Inc.Psychiatric Manifestations of Creutzfeldt-JakobDisease: A 25-Year AnalysisChristopher A. Wall, M.D., Teresa A. Rummans, M.D.,Allen J. Aksamit, M.D.,Lois E. Krahn, M.D. and V. Shane Pankratz, Ph.D.Received April 20, 2004; revised September 9, 2004;accepted September 13,2004. From the Mayo Clinic, Department of Psychiatryand Psychology,Rochester, Minnesota; Mayo Clinic, Department ofNeurology, Rochester,Minnesota. Address correspondence to Dr. Wall, MayoClinic, Department ofPsychiatry and Psychology, Mayo Building-W11A, 200First St., SW, Rochester,MN 55905; wall.chris@mayo.edu (E-mail).This study characterizes the type and timing ofpsychiatric manifestationsin sporadic Creutzfeldt-Jakob disease (sCJD).Historically, sCJD has beencharacterized by prominent neurological symptoms, whilethe variant form(vCJD) is described as primarily psychiatric inpresentation and course: Aretrospective review of 126 sCJD patients evaluated atthe Mayo Clinic from1976-2001 was conducted. Cases were reviewed forsymptoms of depression,anxiety, psychosis, behavior dyscontrol, sleepdisturbances, andneurological signs during the disease course. Eightypercent of the casesdemonstrated psychiatric symptoms within the first 100days of illness, with26% occurring at presentation. The most commonlyreported symptoms in thispopulation included sleep disturbances, psychoticsymptoms, and depression.Psychiatric manifestations are an early and prominentfeature of sporadicCJD, often occurring prior to formal diagnosis.snip...CONCLUSIONSHistorically, psychiatric manifestations have beendescribed as a relativelyinfrequent occurrence in the sporadic form ofcreutzfeldt-Jakob disease.However, our findings suggest otherwise. In this study,a vast majority ofthe cases were noted to have at least one psychiatricsymptom during thecourse of illness, with nearly one-quarter occurring inthe prodromal orpresenting phase of the illness. After comparing thefrequency ofneuropsychiatric symptoms in sporadic CJD to studiesdescribing the variantform of CJD, we found that there are fewer clinicaldifferences thanpreviously reported.5-7 While the age of patientswith vCJD presentationis significantly younger and the course of illness islonger, the type andtiming of psychiatric manifestations appear similarbetween these twodiseases. ...snip...http://neuro.psychiatryonline.org/cgi/content/abstract/17/4/489Personal Communication-------- Original Message -------- Subject: re-BSE prions propagate aseither variant CJD-like or sporadic CJD Date: Thu, 28Nov 2002 10:23:43-0000 From: "Asante, Emmanuel A" To:"'flounder@wt.net'"Dear Terry,I have been asked by Professor Collinge to respond toyour request. I ama Senior Scientist in the MRC Prion Unit and the leadauthor on thepaper. I have attached a pdf copy of the paper for yourattention. Thankyou for your interest in the paper.In respect of your first question, the simple answeris, yes. As youwill find in the paper, we have managed to associatethe alternatephenotype to type 2 PrPSc, the commonest sporadic CJD.It is too early to be able to claim any furthersub-classification inrespect of Heidenhain variant CJD or Vicky Rimmer'sversion. It willtake further studies, which are on-going, to establishif there aresub-types to our initial finding which we are nowreporting. The mainpoint of the paper is that, as well as leading to theexpected newvariant CJD phenotype, BSE transmission to the129-methionine genotypecan lead to an alternate phenotype which isindistinguishable from type2 PrPSc.I hope reading the paper will enlighten you more on thesubject. If Ican be of any further assistance please to not hesitateto ask. Best wishes.Emmanuel Asante<> ____________________________________Dr. Emmanuel A Asante MRC Prion Unit & NeurogeneticsDept. ImperialCollege School of Medicine (St. Mary's) Norfolk Place,LONDON W2 1PGTel: +44 (0)20 7594 3794 Fax: +44 (0)20 7706 3272 email:e.asante@ic.ac.uk (until 9/12/02)New e-mail: e.asante@prion.ucl.ac.uk (active from now)____________________________________Full Text Diagnosis and Reporting of Creutzfeldt-Jakob DiseaseSingeltary, Sr et al.JAMA.2001; 285: 733-734 http://jama.ama-assn.org/cgi/content/full/285/6/733?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=dignosing+and+reporting+creutzfeldt+jakob+disease&searchid=1048865596978_1528&stored_search=&FIRSTINDEX=0&journalcode=jamaTSS #################### https://lists.aegee.org/bse-l.html ####################
Latest Information (as of July 4, 2006 - 17:30 EST)Final test results have confirmed bovine spongiform encephalopathy (BSE) ina mature cross-bred beef cow from Manitoba.The Canadian Food Inspection Agency (CFIA) is conducting a comprehensiveinvestigation. Officials have confirmed the animal was purchased by theowner as part of an assembled group of cattle in 1992. This means that theanimal was at least 15 years of age and would have been born well before the1997 introduction of Canada’s feed ban.As a priority, investigators are attempting to locate the birth farm, whichwill provide the basis needed to identify the animal’s herdmates and feed towhich it may have been exposed at a young age. Given the animal’s age,investigative efforts may be constrained by few surviving animals andlimited sources of information, such as detailed records. A calf born to theaffected animal in 2004 is also being traced.--------------------------------------------------------------------------------http://www.inspection.gc.ca/english/anima/heasan/disemala/bseesb/situatione.shtmlTSS
##################### Bovine Spongiform Encephalopathy #####################Subject: MAD COW FEED RECALLS ENFORCEMENT REPORT FOR AUGUST 9, 2006 KY, LA, MS, AL, GA, AND TN 11,000+ TONSDate: August 16, 2006 at 9:19 am PST RECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINE - CLASS II______________________________PRODUCTBulk custom made dairy feed, Recall # V-115-6CODENoneRECALLING FIRM/MANUFACTURERHiseville Feed & Seed Co., Hiseville, KY, by telephone and letter on or about July 14, 2006. FDA initiated recall is ongoing. REASONCustom made feeds contain ingredient called Pro-Lak which may contain ruminant derived meat and bone meal.VOLUME OF PRODUCT IN COMMERCEApproximately 2,223 tonsDISTRIBUTIONKY ______________________________PRODUCTBulk custom made dairy feed, Recall # V-116-6CODENoneRECALLING FIRM/MANUFACTURERRips Farm Center, Tollesboro, KY, by telephone and letter on July 14, 2006. FDA initiated recall is ongoing.REASONCustom made feeds contain ingredient called Pro-Lak which may contain ruminant derived meat and bone meal.VOLUME OF PRODUCT IN COMMERCE1,220 tonsDISTRIBUTIONKY ______________________________PRODUCTBulk custom made dairy feed, Recall # V-117-6CODENoneRECALLING FIRM/MANUFACTURERKentwood Co-op, Kentwood, LA, by telephone on June 27, 2006. FDA initiated recall is completed.REASONPossible contamination of animal feed ingredients, including ingredients that are used in feed for dairy animals, with ruminant derived meat and bone meal.VOLUME OF PRODUCT IN COMMERCE40 tonsDISTRIBUTIONLA and MS ______________________________PRODUCTBulk Dairy Feed, Recall V-118-6CODENoneRECALLING FIRM/MANUFACTURERCal Maine Foods, Inc., Edwards, MS, by telephone on June 26, 2006. FDA initiated recall is complete.REASONPossible contamination of animal feed ingredients, including ingredients that are used in feed for dairy animals, with ruminant derived meat and bone meal. VOLUME OF PRODUCT IN COMMERCE7,150 tonsDISTRIBUTIONMS ______________________________PRODUCTBulk custom dairy pre-mixes, Recall # V-119-6CODENoneRECALLING FIRM/MANUFACTURERWalthall County Co-op, Tylertown, MS, by telephone on June 26, 2006. Firm initiated recall is complete.REASONPossible contamination of dairy animal feeds with ruminant derived meat and bone meal.VOLUME OF PRODUCT IN COMMERCE87 tonsDISTRIBUTIONMS ______________________________PRODUCTBulk custom dairy pre-mixes, Recall # V-120-6CODENoneRECALLING FIRM/MANUFACTURERWare Milling Inc., Houston, MS, by telephone on June 23, 2006. Firm initiated recall is complete.REASONPossible contamination of dairy animal feeds with ruminant derived meat and bone meal.VOLUME OF PRODUCT IN COMMERCE350 tonsDISTRIBUTIONAL and MS ______________________________PRODUCTa) Tucker Milling, LLC Tm 32% Sinking Fish Grower, #2680-Pellet, 50 lb. bags, Recall # V-121-6;b) Tucker Milling, LLC #31120, Game Bird Breeder Pellet, 50 lb. bags, Recall # V-122-6;c) Tucker Milling, LLC #31232 Game Bird Grower, 50 lb. bags, Recall # V-123-6;d) Tucker Milling, LLC 31227-Crumble, Game Bird Starter, BMDMedicated, 50 lb bags, Recall # V-124-6;e) Tucker Milling, LLC #31120, Game Bird Breeder, 50 lb bags,Recall # V-125-6;f) Tucker Milling, LLC #30230, 30 % Turkey Starter, 50 lb bags, Recall # V-126-6;g) Tucker Milling, LLC #30116, TM Broiler Finisher, 50 lb bags, Recall # V-127-6 CODEAll products manufactured from 02/01/2005 until 06/20/2006RECALLING FIRM/MANUFACTURERRecalling Firm: Tucker Milling LLC, Guntersville, AL, by telephone and visit on June 20, 2006, and by letter on June 23, 2006.Manufacturer: H. J. Baker and Brothers Inc., Stamford, CT. Firm initiated recall is ongoing.REASONPoultry and fish feeds which were possibly contaminated with ruminant based protein were not labeled as "Do not feed to ruminants".VOLUME OF PRODUCT IN COMMERCE7,541-50 lb bagsDISTRIBUTIONAL, GA, MS, and TN END OF ENFORCEMENT REPORT FOR AUGUST 9, 2006 ### http://www.fda.gov/bbs/topics/ENFORCE/2006/ENF00964.html GOTTA LOVE THOSE FDA/USDA TRIPLE BSE FIREWALLS. ...TSS WE know now, and we knew decades ago, that 5.5 grams of suspect feed in TEXAS was enough to kill 100 cows ; http://www.fda.gov/bbs/topics/NEWS/2001/NEW00752.html NOT TO FORGET THE TEXAS MAD COW THAT DID GET AWAY ; http://www.fda.gov/bbs/topics/news/2004/NEW01061.html look at the table and you'll see that as little as 1 mg (or 0.001 gm) caused 7% (1 of 14) of the cows to come down with BSE; Risk of oral infection with bovine spongiform encephalopathy agent in primates Corinne Ida Lasmézas, Emmanuel Comoy, Stephen Hawkins, Christian Herzog, Franck Mouthon, Timm Konold, Frédéric Auvré, Evelyne Correia, Nathalie Lescoutra-Etchegaray, Nicole Salès, Gerald Wells, Paul Brown, Jean-Philippe Deslys Summary The uncertain extent of human exposure to bovine spongiform encephalopathy (BSE)--which can lead to variant Creutzfeldt-Jakob disease (vCJD)--is compounded by incomplete knowledge about the efficiency of oral infection and the magnitude of any bovine-to-human biological barrier to transmission. We therefore investigated oral transmission of BSE to non-human primates. We gave two macaques a 5 g oral dose of brain homogenate from a BSE-infected cow. One macaque developed vCJD-like neurological disease 60 months after exposure, whereas the other remained free of disease at 76 months. On the basis of these findings and data from other studies, we made a preliminary estimate of the food exposure risk for man, which provides additional assurance that existing public health measures can prevent transmission of BSE to man. snip... BSE bovine brain inoculum 100 g 10 g 5 g 1 g 100 mg 10 mg 1 mg 0·1 mg 0·01 mg Primate (oral route)* 1/2 (50%) Cattle (oral route)* 10/10 (100%) 7/9 (78%) 7/10 (70%) 3/15 (20%) 1/15 (7%) 1/15 (7%) RIII mice (ic ip route)* 17/18 (94%) 15/17 (88%) 1/14 (7%) PrPres biochemical detection The comparison is made on the basis of calibration of the bovine inoculum used in our study with primates against a bovine brain inoculum with a similar PrPres concentration that was inoculated into mice and cattle.8 *Data are number of animals positive/number of animals surviving at the time of clinical onset of disease in the first positive animal (%). The accuracy of bioassays is generally judged to be about plus or minus 1 log. ic ip=intracerebral and intraperitoneal. Table 1: Comparison of transmission rates in primates and cattle infected orally with similar BSE brain inocula Published online January 27, 2005 http://www.thelancet.com/journal/journal.isa It is clear that the designing scientists must also have shared Mr Bradley’s surprise at the results because all the dose levels right down to 1 gram triggered infection. http://www.bseinquiry.gov.uk/files/ws/s145d.pdf 2 6. It also appears to me that Mr Bradley’s answer (that it would take less than say 100 grams) was probably given with the benefit of hindsight; particularly if one considers that later in the same answer Mr Bradley expresses his surprise that it could take as little of 1 gram of brain to cause BSE by the oral route within the same species. This information did not become available until the "attack rate" experiment had been completed in 1995/96. This was a titration experiment designed to ascertain the infective dose. A range of dosages was used to ensure that the actual result was within both a lower and an upper limit within the study and the designing scientists would not have expected all the dose levels to trigger infection. The dose ranges chosen by the most informed scientists at that time ranged from 1 gram to three times one hundred grams. It is clear that the designing scientists must have also shared Mr Bradley’s surprise at the results because all the dose levels right down to 1 gram triggered infection. http://www.bseinquiry.gov.uk/files/ws/s147f.pdf Re: BSE .1 GRAM LETHAL NEW STUDY SAYS via W.H.O. Dr Maura Ricketts [BBC radio 4 FARM news] http://www.maddeer.org/audio/BBC4farmingtoday2_1_03.ram http://www.fda.gov/ohrms/dockets/ac/03/slides/3923s1_OPH.htm 2) Infectious dose: To cattle: 1 gram of infected brain material (by oral ingestion) http://www.inspection.gc.ca/english/sci/bio/bseesbe.shtml Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518 [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirement for the Disposition of Non-Ambulatory Disabled Cattle 03-025IFA03-025IFA-2Terry S. Singeltary Page 1 of 17 From: Terry S. Singeltary Sr. [flounder9@verizon.net] Sent: Thursday, September 08, 2005 6:17 PM To: fsis.regulationscomments@fsis.usda.gov Subject: [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirements for the Disposition of Non-Ambulatory Disabled Cattle Greetings FSIS, I would kindly like to submit the following to [Docket No. 03-025IFA] FSIS Prohibition of the Use of Specified Risk Materials for Human Food and Requirements for the Disposition of Non-Ambulatory Disabled Cattle THE BSE/TSE SUB CLINICAL Non-Ambulatory Disabled Cattle Broken bones and such may be the first signs of a sub clinical BSE/TSE Non-Ambulatory Disabled Cattle ; SUB CLINICAL PRION INFECTION MRC-43-00 Issued: Monday, 28 August 2000 NEW EVIDENCE OF SUB-CLINICAL PRION INFECTION: IMPORTANT RESEARCH FINDINGS RELEVANT TO CJD AND BSE Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518 9/13/2005 http://www.fsis.usda.gov/OPPDE/Comments/03-025IFA/03-025IFA-2.pdf TSS#################### https://lists.aegee.org/bse-l.html ####################